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It's a dangerous business, Frodo, going out your door.  
You step onto the road, and if you don't keep your feet, 
 there's no knowing where you might be swept off to. 
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ABSTRACT 
 
Parkinson’s disease (PD) is a neurodegenerative disorder affecting seven to ten million 
people worldwide. The average age of diagnosis is 60, but some forms can affect even young 
adults. In the US alone the direct and indirect expenses for PD exceed $25 billion each year. PD 
is best characterized by the death of dopaminergic neurons of the substantia nigra pars compacta, 
which causes symptoms ranging from rigidity to postural instability. As the disease progresses, 
other areas of the brain become affected, generating psychiatric and cognitive dysfunctions. 
Current therapies effectively reduce motor symptoms of PD, but do not stop its progres-
sion. Neurotrophic factors regulate neuronal growth, differentiation, and survival, and several of 
them have been shown to protect and regenerate dopaminergic neurons in animal models of PD. 
The glial cell line-derived neurotrophic factor (GDNF) and neurturin (NRTN) have reached clini-
cal trials, but they did not replicate the promising results of the preclinical studies. 
Several reasons, including stability of recombinant proteins and their diffusion in the 
brain tissue, could explain the results of the clinical trials. Stability might have been a problem 
especially with GDNF, which has been delivered mostly as bacterially-produced recombinant 
protein. In this work we analysed GDNF produced in mammalian cells and compared it to bacte-
rially-produced GDNF. E. coli produced-GDNF is less stable than mammalian GDNF. This dif-
ference is probably due to the purification/renaturation method used with the E. coli-produced 
factor. Processing and stability of GDNF are affected also by cell line and medium used for its 
production. In mammalian cells glycosylation of GDNF is fundamental for its processing into the 
mature molecule.  
The diffusion problem affects both GDNF and NRTN, which do not diffuse far enough 
from the infusion site because of their heparin-binding properties. Heparin and the closely related 
heparan sulphates are abundant in the extracellular matrix and on the cell surface, and hinder the 
diffusion of GDNF and NRTN. The diffusion issue might not be a significant problem in the 
animal experiments, but might limit the results achieved with humans, who have significantly 
bigger brain size compared to rats and monkeys. In this work we have developed NRTN mutant 
variants with lower affinity for heparin and characterized their activity in vitro and in a unilateral 
6-OHDA rat model of PD. All NRTN variants were biologically active. Especially the variant N4 
showed better diffusion and rescued a higher number of dopaminergic fibres than E. coli-
produced GDNF. Toxin-treated rats administered with N4 also showed functional recovery in 
behavioural assays. However, as a caveat the mutations introduced could have drawbacks influ-
encing NRTN recycling/degradation and signalling. In this respect lack of heparin-binding could 
affect NRTN accumulation on the cell surface and inside the cells, therefore causing a slower 
initiation of the signal. 
Taken together our results help understanding basic features of GDNF and NRTN, such 
as the roles of glycosylation and of heparin binding. They also point out several important fea-
tures that have to be taken into account when producing and/or modifying growth factors for 
clinical use, and underlines that mammalian molecules with reduced heparin binding could be 
beneficial for treating PD patients. 
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LITERATURE REVIEW 
 
1. Parkinson's disease and its treatment 
 Parkinson's disease (PD) is a slowly developing neurodegenerative disorder that is best 
characterized by the degeneration and death of dopaminergic neurons in the substantia nigra pars 
compacta (SNpc). The clinical signs of PD, however, appear only after 50-70% of nigral dopa-
minergic neurons are lost. The largest loss of neurons seems to occur within the early phases of 
the disease, with only little degeneration at later time points. During the early phase also 35-75% 
of striatal fibres are lost (Kordower et al., 2013). The degeneration of these neurons causes im-
pairment of motor function, with symptoms such as rigidity, resting tremor, slow movements 
(bradykinesia), postural instability, and difficulties in walking. In addition to these primary motor 
symptoms, patients develop also secondary motor symptoms which include freezing of gait, 
drooling, reduced facial expression, micrographia, and speech difficulties. As the disease pro-
gresses, additional brain areas are involved, resulting in a disruption of cognitive functions, often 
with dementia occurring in later stages. In addition, PD patients commonly present also signs of 
depression, lack of motivation, sleep disorders, and several other non-motor symptoms, some of 
which often manifest before motor symptoms (Thomas and Beal, 2007). PD is more common in 
elderly people: according to the Parkinson’s Disease foundation the average age of diagnosis is 
60 and only 4% of patients show symptoms before the age of 50, but some genetic forms have an 
earlier onset and can affect even younger adults (Table 1). It is estimated that seven to ten million 
people worldwide are affected by PD and that 60000 new cases are diagnosed every year in the 
US only. The direct and indirect costs of PD sum up to $25 billion dollars/year in the US only, 
and a patient can spend $2500/year for medicines and $100000 for surgery treatment. 
 One of the hypotheses on the pathogenesis of PD states that the disease develops first in 
the medulla oblongata/pontine tegmentum and olfactory bulb/anterior olfactory nucleus. Only 
later the midbrain (and especially the dopaminergic neurons in the SNpc) is involved in the pro-
gression of the disease and the motor symptoms, which are usually the first to be noticed, appear. 
In the last stage, also the neocortex degenerates, causing cognitive decline (Braak et al., 2004).  
 In most cases the degenerating neurons contain aggregates of proteins which include 
misfolded α-synuclein and are known as Lewy bodies, but at the moment it is unclear whether 
these aggregates are responsible for the death of the cell or have a neuroprotective function 
(Engelender, 2008). It has also been suggested that misfolded α-synuclein could act in a prion-
like fashion and spread transneuronally (Desplats et al., 2009). However, it must also be taken 
into account that α-synuclein might not be the cause of the disease, but just a consequence. Stud-
ies on the progression of PD have pointed out that Lewy bodies are more common in unmyelinat-
ed cells which have a long and thin axon compared to their soma (Braak et al., 2004). It has also 
been suggested a correlation between the energy expense of the cell and the presence of the ag-
gregates, with myelinated cells using less energy to transmit impulses along their axon, and being 
less susceptible to the presence of Lewy bodies. Dopaminergic neurons, instead, have massive 
unmyelinated axon arbours, and therefore require more energy than myelinated neurons. The 
main implication of this is that even small perturbations of energy production can cause cell 
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death in this neuronal type (Pissadaki and Bolam, 2013). Moreover, myelinated cells interact with 
oligodendrocytes, which could protect them from degeneration (Braak et al., 2004).  
Although in the majority (90-95%) of cases PD is a sporadic disease with unclear causes, 
most of the genes that are known to be mutated in the early-onset forms of familial PD are related 
to mitochondrial and proteasomal functions, and to protein aggregation (Table 1). Therefore mal-
functioning of mitochondria, proteasomes and/or dysregulation of protein aggregation have been 
hypothesized also for the late-onset sporadic cases (Thomas and Beal, 2007).  
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Locus Gene Inheritance (Probable) function 
PARK1  
4q22.1 
α-synuclein AD Presynaptic protein, Lewy bodies 
PARK2 
6q26 
Parkin AR Ubiquitin E3 ligase 
PARK3 
2p13 
Unknown AD Unknown 
PARK4 
4q22.1 
α-synuclein (gene triplication) AD Presynaptic protein, Lewy bodies 
PARK5 
4p13 
UCH-L1 AD Ubiquitin C-terminal hydrolase 
PARK6 
1p36.12 
PINK1 AR Mitochondrial kinase 
PARK7 
1p36.23 
DJ-1 AR Chaperone, antioxidant 
PARK8 
12q12 
LRRK2 AD Mixed lineage kinase 
PARK9 
1p36.13 
ATP13A2 AR Lysosomal type 5 ATPase 
PARK10 
1p32 
Unknown AD Unknown 
PARK11 
2q37.1 
GIGYF2 AD Role in IGF pathway 
PARK12 
Xq21-q25 
Unknown Unknown Unknown 
PARK13 
2p13.1 
HTRA2 AD Mitochondrial serine protease 
PARK14 
22q13.1 
PLA2G6 AR Phospholipase A2 
PARK15 
22q12.3 
FBXO7 AR Component of modular E3 ubiquitin protein ligase 
PARK16 
1q32 
Unknown Unknown Unknown 
PARK17 
16q11.2 
VPS35 AD 
Trans-Golgi trafficking and recycling of mem-
brane-associated proteins 
PARK18 
3q27.1 
EIF4G1 AD Translation initiation factor 
PARK19 
1p31.3 
DNAJC6 AR Clathrin-mediated endocytosis 
PARK20 
21q22.11 
SYNJ1 AR Clathrin-coated pit dynamics 
 
Table 1. List of familial forms of Parkinson’s disease (PD). Loci, genes, inheritance and probable func-
tions are reported. Search for inherited forms of PD was performed using the Online Mendelian inheritance 
in man (OMIM) search engine (http://www.omim.org/). Abbreviations: AD: Autosomal dominant, AR: 
Autosomal recessive, ATP13A2: ATPase, type 13A2, DJ-1: Oncogene DJ1, DNAJC60: DNAJ/HSP40 
homolog, subfamily C, member 6, EIF4G1: Eukaryotic translation initiation factor 4-γ, FBXO7: F box 
protein 7, GIGYF2: PERQ amino acid-rich with GYF domain-containing protein 2, HTRA2: HTRA serine 
peptidase 2, LRRK2: Leucine-rich repeat kinase 2, PLA2G6: Phospholipase A2, group VI, PINK1: Perk-
induced putative kinase 1, SYNJ1: Synaptojanin 1, UCH-L1: Ubiquitin C-terminal hydrolase, VPS35: 
Vacuolar protein sorting 35. 
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Despite the cause of degeneration not being clear, much is known about the brain areas 
that degenerate in PD, and on the reason why this degeneration causes the symptoms. As the 
most prominent symptoms of PD are related to movement, and the majority of treatments focus 
on relieving motor problems, this paragraph will shortly deal with the circuitry involved (Figure 
1). Movement impairment is due to the degeneration of the dopaminergic neurons of the SNpc. 
This is a region located in the basal ganglia which has a fundamental role in the circuitry regulat-
ing movement. Shortly, sensory inputs that reach the cortex enter the basal ganglia through the 
dorsal striatum, which projects both directly and indirectly (via the external pallidum and the 
subthalamic nucleus) to the internal pallidum and to the substantia nigra pars reticulata (SNpr, the 
efferent nuclei). These have inhibitory projections to the thalamus, which then projects back to 
the cortex, more precisely to the areas involved in movement. The outcome depends on the bal-
ance between the direct and indirect pathway, with the former being facilitating on the thalamus, 
and the latter being inhibitory (Obeso et al., 2008). The dopaminergic neurons located in the 
SNpc project to striatal neurons. The dopamine they release regulates the activity of the striatum 
and it is therefore extremely important for the overall basal ganglia activity. If this is disrupted, 
the cortex is not able to control movement execution, and this leads to the motor symptoms ob-
served in PD. More specifically, degeneration and death of dopaminergic neurons cause a de-
crease of thalamic activity. Moreover, lack of dopamine causes problems with regulation of syn-
aptic transmission, which is mediated by neurons of the indirect pathway which express dopa-
mine receptors (Obeso et al., 2008). 
 
Figure 1. Schematic organization of the basal ganglia show-
ing the most important structures and their projections. 
Striatum receives excitatory inputs from the cortex and has 
inhibitory connections to the internal pallidum (GPi)/SNpr, 
which inhibit the thalamus. The net result of this direct pathway 
is a facilitation of thalamic excitatory signalling to the cortex. 
Striatum also inhibits the external pallidum (GPe), which has 
inhibitory connections to the subthalamic nucleus (STN). This 
has excitatory connections to GPi/SNpr. Striatal inputs along the 
indirect pathway result therefore in facilitation of STN activity, 
leading to activation of GPi/SNpr and inhibition of thalamus. 
The activity of the striatum is regulated by the projection com-
ing from SNpc. Neurons belonging to this structure release do-
pamine on the striatum, with effects that can be either inhibitory 
or facilitatory depending on the receptors present on the post-
synaptic neurons. 
 
1.1 Drug development: from animal models to clinical trials 
There are several treatments available for PD patients (see section 1.2). However, these 
treatments act efficiently on the symptoms of PD, but do not stop or even slow down the progres-
sion of the disease. Therefore new, hopefully more effective, treatments are continuously under 
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development (see sections 1.3, 5 and subsections therein). When a new drug is developed, it is 
first tested in animal models. When the treatment has proven beneficial on animals, the clinical 
trial phase starts, and the drug is tested in humans. Animal models of PD have been developed 
for instance in C. elegans, drosophila, zebrafish, mouse, rat, and monkey. As the clinical trials are 
started only when a molecule has proven beneficial in at least two mammalian models (of which 
one should be a rodent and one a non-rodent species), this paragraph will deal with some of the 
rodent and monkey models of PD. 
The most commonly used models of PD are toxin-induced. 6-hydroxydopamine (6-
OHDA) was discovered more than 45 years ago, and is still widely used, especially in rats. The 
structure of 6-OHDA is similar to that of dopamine, but the additional hydroxyl group causes 
generation of reactive oxygen species, and subsequent neurotoxicity. 6-OHDA has a high affinity 
for both dopamine transporter and noradrenaline transporter. Therefore it is usually administered 
together with inhibitors of noradrenalin reuptake, in order to spare the non-dopaminergic neurons. 
6-OHDA does not pass the blood-brain barrier (BBB). This is the reason why the molecule is 
injected in the striatum (or sometimes in SNpc) in rats, where it destroys the dopaminergic pro-
jections to striatum and the somas of dopaminergic neurons, with dose-dependent effects. 6-
OHDA is effective in reducing dopaminergic fibres and amount of dopamine, and animal models 
show neurobehavioral defects, however, it does not replicate all of the features of PD. For in-
stance, the animals do not show Lewy bodies or α-synuclein aggregates. Injection of 6-OHDA is 
performed unilaterally, because when the toxin is injected bilaterally it has severe consequences 
ranging from aphagia and seizures to death. Moreover, unilateral injection is useful because it 
allows to compare the lesioned with the unlesioned side, and allows rotational assessment of the 
lesion. 6-OHDA is naturally produced in the body, and it has been proposed that it could have a 
role in the pathogenesis of PD. However, no evidence for this has been found yet (Blesa et al., 
2012). 
Another widely used toxin model is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). The importance of this molecule was discovered during 1980s, when a group of young 
drug addicts tried to synthesize drugs at home. They however committed mistakes during the 
synthesis process, which resulted in MPTP contamination and subsequent development of PD 
symptoms. MPTP crosses the BBB so it can be administered systemically (bilateral PD) or via 
the carotid artery (unilateral PD). MPTP is mostly used in non-human primates and mice, as rats 
do not respond to the toxin. MPTP is metabolized to 1-methyl-4-phenylpyridinium (MPP+) by 
the astrocytes and enters dopaminergic neurons through the dopamine transporter. Here, it inhib-
its the mitochondrial electron transport chain, leading to energy failure and oxidative stress. 
MPP+ is also stored in vesicles, where it is thought to cause expulsion of dopamine into the in-
tercellular space. This dopamine is then metabolized to several compounds, including toxic ones. 
Some studies have shown that MPTP causes also formation of Lewy body-like structures, but 
they have been difficult to reproduce (Blesa et al., 2012). 
Other studies have used herbicides like paraquat or rotenone. The structure of paraquat is 
similar to MPP+, and reports have shown that also their modes of action are similar. However, 
paraquat causes formation of Lewy body-like structures and accumulation of α-synuclein in do-
paminergic neurons. Rotenone has been shown to cause damage to dopaminergic neurons, for-
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mation of Lewy body-like structures, accumulation of α-synuclein in dopaminergic neurons, and 
gastrointestinal problems, especially after intravenous administration. Rotenone is not specific for 
dopaminergic neurons and affects also other brain areas, but as PD also affects several neuron 
types, use of rotenone is considered to recapitulate better PD pathogenesis. However, there is 
contrasting evidence on the depletion of dopamine in rat brains, and therefore this model is not 
considered to be superior to the 6-OHDA or MPTP models (Blesa et al., 2012). 
One of the main problems of toxin- or herbicide-induced models is that they do not reca-
pitulate exactly PD pathogenesis. PD is a slowly progressing disease, while toxin-induced lesions 
develop over a much shorter time. Therefore, efforts to create genetic models of PD have been 
made. At the moment mouse models with mutation of α-synuclein, LRRK2, PINK1, parkin, and 
DJ-1 are available (see Table 1 for a summary of their function). Knock-out of α-synuclein does 
not lead to PD-like phenotype, but the A53T mutation has been shown to cause olfactory and 
motor symptoms, formation of Lewy bodies, and colon dysfunction in mice. Despite LRRK2, 
PINK1, parkin, and DJ-1 being mutated in humans, mice models with these mutations have only 
mild phenotype (and sometimes no apparent phenotype at all). These models still need further 
development, but it has been suggested that they could be useful to study susceptibility to exter-
nal factors (Blesa et al., 2012). 
Toxin-induced animal models of PD can be used to predict whether a substance has neu-
roprotective or neurorestorative effects. In the first case the prospective drug is administered be-
fore lesioning the animal, in the second case it is administered after the lesion has developed. The 
efficacy of the molecule is evaluated through several immunohistochemical and functional tests, 
and unilateral lesion models are especially good for this purpose, as the unlesioned side can serve 
as control for the lesioned side (Blesa et al., 2012). Immunohistochemistry is used for instance to 
evaluate the amount of markers such as tyrosine hydroxylase (TH)-positive neurons (i.e. of do-
paminergic neurons, which express TH, the rate limiting enzyme for the synthesis of dopamine), 
dopamine transporter, and dopamine and its metabolites, and to calculate the dopaminergic fibre 
density. Toxin administration causes a decrease in these markers, but if the prospective drug is 
effective, the decrease is smaller (or ideally absent). However, presence of markers does not nec-
essarily indicate that the dopaminergic system is working efficiently. For this reason it is im-
portant to perform also functional tests. Several substances are used to induce rotational behav-
iour in the animal model: the more severe the lesion, the more the animal will rotate. Decrease in 
the amount of rotations indicates a positive treatment effect. Stimulants such as amphetamine 
cause turning ipsilateral to the lesion, while small amounts of apomorphine cause rotations con-
tralateral to the lesion (Von Voigtlander and Moore, 1973). The behavioural difference depends 
on the mode of action of the stimulants. Amphetamine causes the release of dopamine, and there-
fore favours the activity of the unlesioned hemisphere (and subsequent rotation towards the le-
sion). Apomorphine instead stimulates postsynaptic D2 dopamine receptors, which are upregulat-
ed in the denervated striatum, thereby causing rotations contralateral to the lesion (Deumens et al., 
2002). The use of amphetamine or apomorphine depends on the expected size of the lesion: apo-
morphine is better at assessing maximal-sized lesions, while amphetamine is used to assess sub-
maximally lesioned animals (Hudson et al., 1993). Another test that is commonly performed in 
rodents is the cylinder test, where animals are placed in a cylinder and the use of their paws is 
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observed. Due to the asymmetry of the unilateral lesion, rats tend to use more the forelimb which 
is ipsilateral to the lesion. If there is neurorestoration, however, both forelimbs are used equally 
(Tillerson et al., 2001). A test which is routinely performed in monkeys is the hand-eye coordina-
tion task, where a robot presents some reward to the monkey. These treats can be non-moving, or 
moving at slow or fast speed. The number of successfully obtained treats in each condition gives 
an estimate of the hand-eye combination (Woltuis et al., 1995). 
If the substance tested is found to have beneficial effects, it can enter the clinical trials. 
According to the guidelines of the Food and Drug Administration, clinical trials are divided in 
several phases with different goals. However, sometimes two phases can be combined together. 
Phase 0 (which is usually combined with Phase 1) is conducted on not more than ten people, and 
aims at measuring the pharmacodynamics and pharmacokinetics of the drug, particularly the half-
life and the bioavailability. The dose administered is subtherapeutic. Phase 1 is also conducted on 
a little number of people, usually healthy volunteers. The drug is administered at low but increas-
ing doses, in order to test its safety. If the drug is safe, it reaches the Phase 2. In this phase, 10-
300 patients are administered therapeutic doses of the medicine, which is tested for efficacy. 
Phase 2 can be further subdivided in Phase 2a (dosing requirements) and 2b (efficacy). Some-
times Phase 1 and Phase 2 are combined together. Efficacy is tested by administering the partici-
pants either the drug or placebo, and comparing the responses. Most of the prospective drugs fail 
during this phase. After Phase 2, the substance enters Phase 3 and is administered to a wider 
number of patients (1000-3000 people), usually in centres located around the world. During 
Phase 3 the efficacy and safety of the drug are tested again. Only after successfully completing 
Phase 3 a drug can be marketed. Long-term effects of drugs are monitored at this stage (Phase 4).  
  
1.2 Available PD treatments 
The most effective treatments for PD available at the moment have an effect on motor 
symptoms of PD, but do not stop the progression of the disease. These treatments usually try to 
restore dopamine signalling, and consequently the activity of the basal ganglia. 
As dopamine does not cross the BBB, the most commonly used medicine is L-3,4-
dihydroxyphenylalanine (L-DOPA), the precursor of dopamine, which is readily absorbed in the 
intestine and is carried to the brain by the bloodstream. In contrast to dopamine, L-DOPA is able 
to cross the BBB through a L-type amino acid transporter (Gomes and Soares-da-Silva, 1999) 
and is taken up and metabolized by the remaining dopaminergic neurons. L-DOPA lowers the 
motor symptoms to the point that they might not be noticed, but can have different side effects, 
ranging from nausea to hallucinations. In addition, it is administered orally and only a small part 
of it (1-3%) reaches the central nervous system (CNS). For these reasons, it is never administered 
alone, but together with peripheral DOPA decarboxylase (DDC) inhibitors that make it possible 
for L-DOPA to remain intact in the periphery for a longer time (Kalinderi et al., 2011). Inhibition 
of peripheral decarboxylases also prevents the conversion of L-DOPA into dopamine, which has 
several effects outside the CNS: for instance it increases renal excretion of sodium and decreases 
production of aldosterone (therefore affecting blood pressure), and reduces gastrointestinal motil-
ity and acid secretion (see for instance Goldstein et al., 1995). Other medicines, such as dopa-
mine agonists or inhibitors of the enzymes that degrade central dopamine (monoamine oxidase, 
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MAO, and catechol-O-methyltransferase, COMT), are used to reduce the amount of L-DOPA 
administered. Domperidone (an anti-dopaminergic drug which does not cross the BBB) is useful 
against nausea (Kalinderi et al., 2011). Another reason why L-DOPA is never administered alone 
is that, after 4-6 years of chronic use, patients develop motor complications which can lead to 
severe disabilities. The use of dopamine agonists and inhibitors of DDC, MAO and COMT al-
lows the use of lower dosages of L-DOPA, which is thought to delay the onset of motor compli-
cations. In Finland, L-DOPA is commonly administered as late as possible, and the therapy starts 
with MAO-B inhibitors (such as rasagiline) or dopamine agonists, especially in patients younger 
than 75 years old. L-DOPA is administered from the beginning only in older patients and people 
showing cognitive symptoms. Eventually, however, every patient has to be treated with L-DOPA 
(see Finnish best practice guidelines at http://www.kaypahoito.fi). 
Another treatment option that has proven beneficial is deep brain stimulation (DBS). This 
technique requires the patient to undergo surgery, and is used when the usual medical treatments 
have severe side effects (Kleiner-Fisman et al., 2006). A pulse generator that interferes with neu-
ronal activity is implanted at the target site (either STN or internal pallidum, depending on the 
patient). The exact mechanism through which DBS relieves the symptoms is not perfectly under-
stood: stimulation in mice has been shown to cause astrocytes to release adenosine triphosphate 
(ATP). This binds inhibitory A1 receptors and has consequences similar to those of ablation, with 
the difference that the effects of DBS are reversible (Bekar et al., 2008). DBS has several side 
effects: haemorrhage and infection are related to the surgery itself, and a study on PD patients 
showed increased problems with learning, attention, and word generation (Kleiner-Fisman et al., 
2006). Moreover, in some cases psychiatric consequences have been observed. These can also be 
due to misplacement of the electrodes, but repositioning, recalibrating or withdrawing the pulse 
generator solves such potential problems. DBS is in use for other conditions beside PD. These 
include chronic pain, dystonia, essential tremor, and depression, and in these cases the pulse gen-
erator is implanted in areas relevant to these conditions (Kringelbach et al., 2007). 
There are several other pharmacological therapies available at the moment. These include 
duodenal administration of L-DOPA, anticholinergic biperiden, and amantadine (see Finnish best 
practice guidelines at http://www.kaypahoito.fi). Biperiden improves muscle rigidity and saliva-
tion, and has a positive effect on abnormal gait and tremor, and amantadine increases dopamine 
release, blocks its reuptake, and reduces L-DOPA side effects (Kalinderi et al., 2011).  
In addition to pharmacological treatments, also rehabilitation and support therapies are in 
use. These include for instance physical therapy, which is effective especially in milder forms of 
the disease. Exercise is useful to improve motor performances, and for instance dancing has been 
shown to improve motor control and balance. Music therapy is also used in some cases. Speech 
therapy is important, as it improves speech quality and voice volume (which tends to get lower in 
PD patients). Speech therapy might have positive effects also in relation to facial expressivity and 
swallowing (see Finnish best practice guidelines at http://www.kaypahoito.fi).  
 
1.3 Towards neurotrophic and neurorestorative therapies 
New studies on PD are conducted continuously in order to improve the already existing 
treatments and to find new ones. As an example, a search on the Thomson Reuters Cortellis™ 
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database retrieves 36 clinical trials started during 2013, and 39 new drugs in the discovery phase 
added during the same period. Several types of drugs have been tested during the years, and some 
of these studies have focused on an extremely important concept: L-DOPA and/or DBS are in-
deed effective in reducing the symptoms, but dopaminergic neurons continue to die as the disease 
progresses. Therefore efforts to find cures that would stop the degeneration of dopaminergic neu-
rons are continuously being made.  
Already during 1980’s clinicians started to consider the possibility of transplanting em-
bryonic stem cells into the brain, in order to substitute the dying neurons. During the years there 
has been debate on the real usefulness of transplants of embryonic neurons and neural progenitor 
cells, with open-label trials showing benefits (sometimes to the point of L-DOPA becoming un-
necessary) but double-blind trials not confirming those results. In addition it has been pointed out 
that transplanted cells do not stop the disease progression, and also the grafted neurons will even-
tually develop the pathology and die. However, further studies have shown that the degree of 
graft pathology is different in different patients, with one case still showing unaffected neurons 
after 14 years. Because of these conflicting results, research on this field slowed down a few 
years ago, but it is now being considered again, provided the techniques used to produce and 
implant neurons will improve (for a list of references, see Lindvall, 2013).  
Another PD treatment option that has been considered suitable is gene therapy. Some of 
the genes that have been delivered encode for enzymes related to the synthesis/catabolism of 
dopamine, like TH, the rate-limiting enzyme in the synthesis of dopamine. Other genes increase 
the endogenous levels of neurotrophic factors, proteins which are produced in extremely limited 
amounts in the brain and are responsible for neuronal growth, survival, and maintenance. Related 
to this, is the possibility to deliver directly neurotrophic factors that are known to protect dopa-
minergic neurons and promote their survival. Several neurotrophic factors have been evaluated 
during the years. These include the basic fibroblast growth factor (bFGF), the epidermal growth 
factor (EGF), the brain-derived neurotrophic factor (BDNF), and the glial cell line-derived neu-
rotrophic factor (GDNF), which has so far been the most widely used growth factor in animal 
models of PD (Lawlor and During, 2004). GDNF and the closely related molecule neurturin 
(NRTN) have reached the phase 2 clinical trials (see sections 5.1 and 5.2) and will be described 
in more detail in sections 2.1 and 2.2.  
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2. GDNF family ligands (GFLs): structure, signalling and function 
GDNF family ligands (GFLs) are conserved neurotrophic factors belonging to the trans-
forming growth factor β (TGFβ) superfamily, despite very low sequence homology with the other 
members of this group. All of them are dimers containing a cysteine (Cys) knot which stabilizes 
the structure of the two composing monomers and the resulting dimer. There are three intramo-
lecular disulphide bonds and one intermolecular bond formed by the fourth Cys of each of the 
monomers (Butte, 2001). 
There are four members in the GFL family: glial cell line-derived neurotrophic factor 
(GDNF, Lin et al., 1993), neurturin (NRTN, Kotzbauer et al., 1996), artemin (ARTN, Baloh et 
al., 1998, Rosenblad et al., 2000) and persephin (PSPN, Milbrandt et al., 1998), which all act as 
homodimers. The crystal structures of GDNF and ARTN have been resolved (Eigenbroth and 
Gerber, 1997, Silvian et al., 2006). GDNF and ARTN have two finger-like structures which are 
composed of two and four β-strands, respectively, and are separated by an α-helix which forms a 
region called heel (Figure 2).  
 
 
Figure 2. Model of the three-dimensional structure of the glial cell line-derived neurotrophic factor 
(GDNF). The two monomers forming the molecule are coloured in light blue and pink, and the disulphide 
bonds are represented in yellow and purple. The fingers and the heel have been also indicated. Picture 
kindly provided by Vimal Parkash. 
 
The receptor complex of GFLs is composed of a glycophosphatidylinositol (GPI)-
anchored receptor called GDNF family receptor alpha (GFRα) and a transmembrane tyrosine 
kinase receptor named RET (REarranged during Transfection), and is depicted in Figure 3. There 
are four different GFRα coreceptors (GFRα1-4), and each of them is specific for a GFL, although 
there is for instance some cross-talk between GDNF and NRTN and their respective receptors 
(Airaksinen and Saarma, 2002). In addition, GFLs can signal through other specific molecules 
present on the cell surface. For instance, they can signal GFRα-dependently through the neural-
cell adhesion molecule (N-CAM, Paratcha et al., 2003), or signal directly via syndecan-3 
(Bespalov et al., 2011). 
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Figure 3. Model of the GFL receptor complex. The receptor 
complex is composed by a GFRα dimer (light green) and a RET 
dimer (purple). The GFL dimer (dark green) binds the co-
receptor GFRα, thus initiating RET-mediated signalling. The 
yellow dot represent Ca2+ bound to RET. 
Abbreviations: GFL: GDNF family ligand, GFRα: GDNF fami-
ly receptor alpha, RET: Rearranged during transfection 
 
The residues that play a role in binding of the re-
ceptor are located on the fingertips (Eketjäll et al., 1999, 
Baloh et al., 2000, Wang et al., 2006, Parkash et al., 2008), 
while the long N-terminal sequence present in GDNF does 
not seem to be important for binding to the receptor com-
plex (Alfano et al., 2007). All GFLs are produced as pre-
proproteins, from which first the pre- and then the prose-
quence are supposed to be cleaved (Airaksinen and Saar-
ma, 2002). 
GFLs have a role in the survival of different neural populations, including dopaminergic, 
enteric, sensory, motor, sympathetic, and parasympathetic neurons (Airaksinen and Saarma, 
2002). In addition they are important also outside the nervous system. For instance, at least 
GDNF and NRTN are important in kidney development (Davies et al., 1999, Costantini and 
Shakya, 2006). 
 
2.1 Glial cell line-derived neurotrophic factor (GDNF) 
GDNF was first isolated from a rat glial cell line, on the basis of its capacity to promote 
survival of dissociated embryonic dopaminergic neurons and dopamine uptake in midbrain cul-
tures. The study showed that GDNF is N-glycosylated and contains disulphide bonds. Neverthe-
less when the recombinant protein was produced in E. coli, purified, and subsequently renaturat-
ed, the resulting unglycosylated protein was active in vitro. GDNF increased the survival of do-
paminergic neurons from dissociated rat embryonic midbrains, increased the dopamine uptake of 
TH-positive neurons, and increased their morphological differentiation and neurite outgrowth 
(Lin et al., 1993). In addition to the aforementioned effects on dopaminergic neurons, GDNF has 
several other functions, including survival, proliferation and migration of several neuron types 
(Sariola and Saarma, 2003). GDNF has roles also outside the nervous system: it is for instance 
important for the development of kidneys (Costantini and Shakya, 2006) and for regulation of 
spermatogenesis (Meng et al., 2000).  
The importance of GDNF and its signalling can be seen in mice lacking the protein. Ho-
mozygote GDNF knock-outs are able to suckle and move, but die shortly after birth. They lack 
enteric nervous system (ENS) and kidneys, and have deficits in dorsal root ganglion (DRG), 
sympathetic, nodose and motor neurons. Interestingly, homozygous GDNF knock-outs do not 
show degeneration of dopaminergic neurons at this time point (Moore et al., 1996, Pichel et al., 
1996, Sánchez et al., 1996). Heterozygous GDNF knock-out mice survive, but have deficits in 
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spermatogenesis (Meng et al., 2000) and learning (Gerlai et al., 2001) in adult age. This demon-
strates that GDNF is not required for development of dopaminergic neurons, but does not explain 
if it is required for their postnatal maintenance. In an attempt to solve this question, grafts of do-
paminergic neurons from the ventral mesencephalon of GDNF knock-outs and heterozygotes 
were transplanted to the denervated striata of wild type adult mice. Results showed that grafts 
from heterozygotes or wild type mice have the same amount of dopaminergic neurons, while 
grafts from homozygotes have fewer dopaminergic neurons (Granholm et al., 2000). Apparently 
contradictory results were obtained in a study on conditional GDNF knock-out mice, where 
GDNF expression was ablated during adulthood. In this study, mice carrying a floxed Gdnf allele 
were bred with heterozygous GDNF knock-out mice carrying the Cre (cause recombination) 
recombinase under a ubiquitous promoter. The resulting GDNFF/-;Cre mice were administered 
tamoxifen at two months of age, and killed 1, 3 or 7 months later. Tamoxifen-induced recombina-
tion caused excision of 82% of the floxed Gdnf alleles, which resulted in levels of GDNF protein 
of about 40% compared to wild type mice. This decrease resulted in dramatic loss of dopaminer-
gic neurons in SNpc and ventral tegmental area, and complete loss of noradrenergic neurons in 
locus coeruleus (Pascual et al., 2008). The amount of GDNF protein in this latter study is roughly 
comparable to the amount of GDNF in heterozygous GDNF knock-out mice. However, the re-
sults of Pascual and colleagues (2008) seem to contrast those of Granholm and colleagues (2000), 
where no difference between heterozygotes and wild type mice was observed. This discrepancy 
could be explained by hypothesizing the establishment of a compensatory neuronal pathway dur-
ing embryonic development in GDNF knock-out mice.  
Alternative splicing of Gdnf mRNA gives rise to two proteins, α-proGDNF and β-
proGDNF, which differ in the length of their prosequences. These are expressed at different lev-
els in various tissues (Suter-Crazzolara and Unsicker, 1994, Grimm et al., 1998), located also 
outside the CNS. A third variant lacking the entire exon 2 has been identified in human embryon-
ic kidney 293 (HEK 293) cells, but it might be specific for that cell line (Grimm et al., 1998). 
Both the longer and the shorter GDNF isoform (α-proGDNF and β-proGDNF, respectively) are 
secreted, but through different mechanisms. The secretion of β-proGDNF increases in a Ca2+-
dependent manner when cells are stimulated with KCl. β-proGDNF localizes within vesicles of 
the regulated secretory pathway. α-proGDNF instead localizes mostly within the Golgi, and its 
secretion is neither depolarization- nor Ca2+-dependent (Lonka-Nevalaita et al., 2010).  
 GDNF, differently from the other GFLs, has a long N-terminus which contains many 
basic residues. These amino acids form a heparin-binding consensus sequence (Cardin and Wein-
traub, 1989, Hileman et al., 1998, Alfano et al., 2007). In addition to heparin, GDNF binds also 
the closely related heparan sulphates (HS), for example the transmembrane heparan sulphated 
proteoglycan (HSPG) syndecan-3 (Bespalov et al., 2011). Some studies suggest that binding to 
HS is fundamental for GDNF signalling (Barnett et al., 2002), however, GDNF mutant variants 
completely lacking the heparin-binding N-terminus are also fully active (Alfano et al., 2007, 
Leung et al., 2012). In addition, the N-terminus of GDNF is important for binding to SorLA 
(Glerup et al., 2013), which is involved in recycling/degradation of the GDNF/GFRα1/RET 
complex. 
Literature review 
16 
Mature GDNF acts as a dimer and binds preferentially the GFRα1 receptor, signalling 
then inside the cell via RET (Jing et al., 1996) or N-CAM (Paratcha et al., 2003). Binding to 
GFRα1, occurs via 14 specific amino acids located on the finger structures (Parkash et al., 2008). 
GDNF can also bind syndecan-3 (Bespalov et al., 2011) and act independently of GFRα1.  
As the pro-forms of some neurotrophic factors, like the brain-derived neurotrophic factor 
(BDNF) and the nerve growth factor (NGF), are known to have a biological activity which differs 
from that of the mature forms, it is surprising that only few studies have focused on the biological 
role of proGDNF. These studies proved that a peptide derived from the prosequence of GDNF 
has biological activity and can protect dopaminergic neurons (Bradley et al., 2010, Kelps et al., 
2011), and that proGDNF can be secreted upon overexpression (Lonka-Nevalaita et al., 2010).  
 
2.2 Neurturin (NRTN) 
NRTN (Kotzbauer et al., 1996) was first discovered based on its ability to promote the 
survival of superior cervical ganglion neurons isolated from neonatal rats. Like GDNF, NRTN is 
important for survival of dopaminergic neurons (Horger et al., 1998), but there might be differ-
ences in their roles, and there are differences in the expression pattern of these growth factors. 
For instance, in adult mice Gdnf, but not Nrtn, mRNA can be detected in the substantia nigra 
(Golden et al., 1998). No extensive studies on the localization of the endogenous protein are 
available. Like GDNF, NRTN has also roles outside the nervous system. However, the molecules 
might act in a different way: for instance, NRTN can induce kidney branching in culture (Davies 
et al., 1999), but NRTN knock-out mice are viable and have morphologically and functionally 
normal kidneys (Heuckeroth et al., 1999). In addition, unlike GDNF which is a paracrine mor-
phogen, NRTN is expressed directly by the developing kidney ducts, and is therefore an auto-
crine factor (Davies et al., 1999). Another difference is in the phenotype of NRTN knock-out 
mice (Heuckeroth et al., 1999): they have deficits in the enteric, parasympathetic and sensory 
systems, but differently from the GDNF knock-outs are viable and fertile. 
NRTN protein sequence has 42% homology with GDNF (Kotzbauer et al., 1996). The 
biggest difference is at the N-terminus, which in GDNF is very long. As GDNF binds heparin 
mainly because of the amino acids present in its long N-terminal extension (Alfano et al., 2007), 
the high affinity of NRTN to heparin must be due to residues located elsewhere. 
As all other GFLs, NRTN is encoded as preproprotein. However, proNRTN is poorly se-
creted, and is apparently not binding neither GFRα1 nor GFRα2 complexed with RET. A NRTN 
construct where the signal peptide is replaced with that of the immunoglobulin G heavy chain 
and which lacks the prosequence has been shown to be secreted much more efficiently than the 
wild type protein (Fjord-Larsen et al., 2005). 
Not much is known about the role of proNRTN. However, a mutation around the cleav-
age site of NRTN has been linked to Hirchsprung’s disease, a disease characterized by lack of 
neurons in the distal segments of the ENS. This mutation causes the substitution of the first ami-
no acid of mature NRTN, changing it from alanine (Ala) to serine (Ser), and could alter the 
cleavage of NRTN. The substitution itself does not cause the disease, but it has been found in 
three affected subjects from the same family that also had a mutation in the RET gene (Doray et 
al., 1998). 
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Mature NRTN acts as a dimer and binds preferentially to the GPI-anchored receptor 
GFRα2, signalling through RET (Baloh et al., 1997, Klein et al., 1997). The presence of GFRα2 
also increases the interaction of NRTN with N-CAM (Paratcha et al., 2003). Like GDNF, NRTN 
can signal also directly via syndecan-3 (Bespalov et al., 2011), and probably NRTN signal can be 
transduced by integrin β-1 too (Schmutlzer et al., 2011). 
 
2.3 Artemin (ARTN) 
 ARTN was discovered based on sequence homology with NRTN. This factor promotes 
survival of a larger number of DRG and trigeminal ganglion neurons compared to GDNF or 
NRTN (Baloh et al., 1998, Rosenblad et al., 2000). ARTN is the only known ligand for GFRα3, 
which is expressed by nociceptors. For this reason, the growth factor has been studied also in 
relation to neuropathic pain (for a review, see Sah et al., 2005). ARTN also promotes the survival 
of E14 rat embryonic dopaminergic neurons of the ventral mesencephalon cultured for three days 
in vitro. Analysis of ARTN expression in rat brains shows that Artn mRNA is not expressed in 
the ventral mesencephalon at this stage. However, there are species-specific (and possibly devel-
opmental) differences, and in humans Artn mRNA is expressed at low levels in the brain, espe-
cially in the basal ganglia and thalamus. Outside the nervous system Artn mRNA is present, for 
instance, in the pituitary gland, placenta and trachea (in adults), and in fetal kidneys and lungs 
(Baloh et al., 1998).  
ARTN is also initially produced as preproprotein. The propeptide is predicted to be 39 
amino acids long, and it contains two additional predicted N-terminal furin cleavage sites. A pu-
tative N-glycosylation site is located at the C-terminus (Rosenblad et al., 2000).  
ARTN acts as a dimer and signals by activating RET through GFRα3 (Baloh et al., 1998). 
The crystal structure of ARTN complexed with GFRα3 has been solved (Silvian et al., 2006). 
ARTN can also signal independently of RET, via GFRα3/N-CAM (Schmutzler et al., 2011). In 
addition, ARTN is the GFL which binds heparin with the highest affinity (Alfano et al., 2007), 
and can bind directly syndecan-3 (Bespalov et al., 2011). 
 
2.4 Persephin (PSPN) 
PSPN (Milbrandt et al., 1998) was identified using polymerase chain reaction (PCR). It 
was shown to promote survival of dopaminergic neurons, and their restoration after 6-OHDA 
lesion. In addition it is important for survival of motor neurons in vitro and in vivo. Outside the 
nervous system it was shown to promote ureteric branching in kidney explants (Milbrandt et al., 
1998).  
Mouse neural progenitor cells (c17.2, originating from cerebellum) overexpressing PSPN 
have been transplanted in striata of mice models of PD to study the function and therapeutic ef-
fects of this factor in vivo. These cells were found to diffuse within the striatum and to give rise 
to neurons, astrocytes and oligodendrocytes. Neuroprotective effects were shown in 6-OHDA-
treated animals. Moreover, mice transplanted with the PSPN-overexpressing cells, but which did 
not receive the toxin, had better motor performance in dopamine-dependent tasks (Åkerud et al., 
2002).  
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Mature PSPN binds GFRα4 causing RET activation (Enokido et al., 1998, Lindahl et al., 
2000, Lindahl et al., 2001). Differently from the other ligands, PSPN does not bind heparin, and 
therefore does not signal through syndecan-3 (Bespalov et al., 2011). However, PSPN has been 
shown to bind GFRα1 (Sidorova et al., 2010) and signal through N-CAM (Paratcha et al., 2003). 
 
Figure 4. Alignment of human 
GFLs. Red: presequence, light 
blue: prosequence, green: finger 
structures, C: cysteines involved 
in the knot, NXX: putative N-
glycosylation sites, X: heparin-
binding region, according to 
Alfano et al., 2007 (GDNF) and 
Silvian et al., 2006 (ARTN), the 
red vertical bars indicate pre-
dicted furin cleavage sites. The 
sequences were aligned using 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/), and then color-coded to mark Cys, N-
glycosylation sites (predicted with NetNGlyc, http://www.cbs.dtu.dk/services/NetNGlyc/), pre- and prose-
quences, and putative furin cleavage sites (predicted with ProP, http://www.cbs.dtu.dk/services/ProP/). 
Abbreviations: ARTN: artemin, GFLs: GDNF family ligands, GDNF: Glial cell line-derived neurotrophic 
factor, NRTN: neurturin, PSPN: persephin  
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3. GFL receptors: structure and mediation of GFLs signalling 
3.1 GDNF family receptor alpha 1-4 (GFRα1-4) 
The four GFRα co-receptors are the main co-receptors for GFLs. Each of them has a pre-
ferred ligand (Figure 5): GFRα1 binds preferentially GDNF (Jing et al., 1996), GFRα2 NRTN 
(Baloh et al., 1997, Buj-Bello et al., 1997, Jing et al., 1997, Klein et al., 1997, Suvanto et al., 
1997), GFRα3 (Jing et al., 1997) ARTN (Baloh et al., 1998, Rosenblad et al., 2000), and GFRα4 
(Thompson et al., 1998) PSPN (Enokido et al., 1998, Lindahl et al., 2000, Lindahl et al., 2001). 
However, cross-talk has been reported: NRTN can bind GFRα1 and signal through it, and the 
same is true for GDNF and GFRα2 (Baloh et al., 1997, Creedon et al., 1997, Jing et al., 1997, 
Sanicola et al., 1997, Trupp et al., 1998, Cik et al., 2000). Also ARTN and PSPN seem to be able 
to bind GFRα1, at least in the presence of RET, which is known to stabilize the receptor complex 
(Carmillo et al., 2005, Sidorova et al., 2010).  
The GFRα co-receptors are GPI-anchored proteins which lack cytoplasmic domains that 
could transduce the signal inside the cells (Figure 5). The presence of of RET or of another recep-
tor with an intracellular domain is therefore fundamental for GFLs to have an effect. However, 
GFLs do not bind RET directly (see for instance Jing et al., 1996), and binding to GFRα co-
receptors is essential for RET signalling.  
 
Figure 5. Binding of GFLs and 
GFRα co-receptors. Preferential bind-
ing is indicated with a thick, straight, 
arrow: GDNF binds GFRα1 (green), 
NRTN GFRα2 (red), ARTN GFRα3 
(blue), and PSPN GFRα4 (orange). 
Less efficient binding, is indicated with 
a thin, straight, arrow: GDNF can bind 
also GFRα2, and NRTN can bind also 
GFRα1. Binding which occurs only in 
the presence of RET (purple) or which 
is still under debate is indicated with 
broken arrows: both ARTN and PSPN 
have been reported to bind GFRα1. 
The yellow dot represents Ca2+ bound 
to RET. The curved arrows indicate binding of the GFL/GFRα complex to RET. For clarity, only one 
GFRα co-receptor and one RET receptor are shown. 
Abbreviations: ARTN: artemin, GDNF: glial cell line-derived neurotrophic factor, GFL: GDNF family 
ligand, GFRα: GDNF family receptor alpha, NRTN: neurturin, PSPN: persephin, RET: rearranged during 
transfection. 
 
Mice lacking GFRα1 have almost the same phenotype as GDNF knock-out mice. They 
show deficits in the same subpopulations of neurons, they lack the ENS below the stomach, and 
the kidneys are absent. In addition, their dissected dopaminergic neurons do not respond to 
GDNF or NRTN in the culture medium, unless they are exposed at the same time to exogenous 
soluble GFRα1 (Cacalano et al., 1998). As mentioned earlier, GDNF can bind GFRα2, however, 
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NRTN GFRα2 (red), ARTN GFRα3 
(blue), and PSPN GFRα4 (orange). 
Less efficient binding, is indicated with 
a thin, straight, arrow: GDNF can bind 
also GFRα2, and NRTN can bind also 
GFRα1. Binding which occurs only in 
the presence of RET (purple) or which 
is still under debate is indicated with 
broken arrows: both ARTN and PSPN 
have been reported to bind GFRα1. 
The yellow dot represents Ca2+ bound 
to RET. The curved arrows indicate binding of the GFL/GFRα complex to RET. For clarity, only one 
GFRα co-receptor and one RET receptor are shown. 
Abbreviations: ARTN: artemin, GDNF: glial cell line-derived neurotrophic factor, GFL: GDNF family 
ligand, GFRα: GDNF family receptor alpha, NRTN: neurturin, PSPN: persephin, RET: rearranged during 
transfection. 
 
Mice lacking GFRα1 have almost the same phenotype as GDNF knock-out mice. They 
show deficits in the same subpopulations of neurons, they lack the ENS below the stomach, and 
the kidneys are absent. In addition, their dissected dopaminergic neurons do not respond to 
GDNF or NRTN in the culture medium, unless they are exposed at the same time to exogenous 
soluble GFRα1 (Cacalano et al., 1998). As mentioned earlier, GDNF can bind GFRα2, however, 
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at least in developing and adult mice (Widenfalk et al., 1997, Wang et al., 2000) and in adult rats 
(Marco et al., 2002), the dopaminergic neurons do not seem to express GFRα2. This is the reason 
why they cannot be rescued by GDNF or NRTN alone. Nevertheless, it has been shown that 
when dopaminergic neurons derived from GFRα1 knock-out mice are exposed to soluble GFRα2, 
they become responsive to both GDNF and NRTN (Wang et al., 2000). Full knock-out of GFRα2 
instead leads to viable mice with a phenotype similar to homozygous NRTN knock-out mice 
(Rossi et al., 1999). Knock-out of GFRα3 suggests that the receptor might have a role in colorec-
tal sensitivity (Tanaka et al., 2011), and GFRα4 knock-outs have reduced thyroid calcitonin lev-
els, which leads to increased bone formation (Lindfors et al., 2006). No effect has been observed 
on the dopaminergic system in the two latter cases. 
 GFRα1-3 consist of three domains (D1-D3) with conserved Cys residues (Jing et al., 
1996, Jing et al., 1997, Suvanto et al., 1997, Thompson et al., 1998). GFRα4 lacks D1, except in 
chicken, and is therefore shorter than the other members of the family (Lindahl et al., 2000). D1, 
when present, is linked to D2 via a hinge region, while the space between D2 and D3 is much 
shorter. These latter domains, but not D1, are important for ligand binding and specificity (Scott 
and Ibáñez, 2001). D2 and D3 have a similar structure with five α-helices and five disulphide 
bridges (Leppänen et al., 2004). The first, second and fourth helices form a triangular spiral, 
while the third packs antiparallelly against the second, and the fifth is a continuation of the fourth. 
Preliminary mutation studies (Scott and Ibáñez, 2001) predicted that the residues 211MLF and 
224RRR located in D2 are important for GDNF binding. Further studies (Leppänen et al., 2004) 
have shown the importance specifically of residues 213, 224, and 225 and 229; mutation of the 
first three leads to lower affinity for GDNF, while the last completely abolishes the binding of the 
molecule and the activation of RET. The same study also found that Arg217 is probably involved 
in binding to RET. Studies on ARTN (Wang et al., 2006) complexed with GFRα3 have shown 
that D2 and D3 are actually part of the same globular domain which they form due to tight hy-
drophobic interactions. The residues involved in these hydrophobic interactions are conserved in 
all GFRα co-receptors, and it has been shown (Parkash et al., 2008) that the same globular do-
main composed by D2 and D3 is present also in GFRα1: D3 stabilizes D2 that is consequently 
able to bind GDNF.  
D1 and D2 contain positively charged sequences which probably mediate heparin bind-
ing. It has been shown (Parkash et al., 2008) that GFRα1 binds heparin with high affinity. This 
affinity decreases without disappearing in mutants lacking D1. Besides this, and the predicted 
presence of four Cys bridges, the structure of D1 is currently unsolved and its role is still not 
clear. In GFRα1 at least, D1 appears to be not fundamental for binding GDNF, but its presence 
stabilizes the interaction of the ligand with the receptor (Virtanen et al., 2005). D1 does not seem 
to be involved in RET binding either (Virtanen et al., 2005); however it appears like the interac-
tion of this domain with the ligand occurs only after the GFL-GFRα-RET complex has formed 
(Amoresano et al., 2005).  
The GPI-anchor can be cleaved by the phosphoinositide-specific phospholipase C (PLC), 
generating soluble forms of the receptor (Yu et al., 1998). This indicates the possibility that 
GFRα co-receptors signal not only in cis but also in trans. It has been shown that GFRα1 is 
cleaved in several types of cells, including neurons and Schwann cells. In the presence of GDNF, 
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soluble GFRα1 potentiates the signalling including recruitment of RET to lipid rafts (Paratcha et 
al., 2001).  
GFRα co-receptors are expressed in many different brain regions and neuron types; here 
I am focusing on the areas of interest for PD. It has been shown that both Gfrα1 and Ret mRNA 
are expressed in the SNpc and striatum of both healthy adults and PD patients (Walker et al., 
1998, Bäckman et al., 2006), supporting the idea of using GDNF and NRTN for the treatment of 
PD. However, expression of the receptors may vary depending on the species or developmental 
stage. For instance, in embryonic and adult mice Gfrα1 mRNA is expressed in dopaminergic 
neurons in SNpc, while Gfrα2 mRNA was found in the substantia nigra, but not specifically in 
dopaminergic cells (Widenfalk et al., 1997). Further analysis of Gfrα2 mRNA expression shows 
that the co-receptor is located in cells close to the deeper migrating neurons in embryos (Wang et 
al., 2000). Gfrα1 mRNA has been found in the striata of developing mice (Nosrat et al., 1997), 
but Gfrα2 mRNA has not been detected in the same area (Widenfalk et al., 1997). Interestingly, 
the expression of GFRα1 and GFRα2 mRNAs in rat SNpc is differently regulated after a single 
striatal injection of 20 µg (4µl) 6-OHDA. GFRα1 levels transiently increase one day after the 
lesion and then decrease three days later, while GFRα2 expression decreases only six days after 
the lesion (Marco et al., 2002). However, data from PD patients indicate that there are no changes 
in the expression levels of GFRα1 in the putamen (Bäckman et al., 2006).  
Some GFRα receptors have also splice variants. GFRα1, for instance, has two splice var-
iants: the longest (GFRα1a) includes a stretch of five residues (140DVFQQ) in the hinge region 
between D1 and D2, while the shortest (GFRα1b) does not. They are differently expressed, for 
instance GFRα1a is predominant in neuronal tissues and in differentiated rat adrenal pheochro-
mocytoma (PC-12) cells, and have a different affinity for GDNF, as GFRα1b seems to bind it 
more efficiently. These five residues are not directly involved in ligand binding, therefore the 
higher affinity of GDNF for GFRα1b could actually reflect an increased stability of the complex 
due to a slightly different conformation of D1. The two isoforms are differently regulated during 
development: for instance in kidney GFRα1b mRNA is predominant before birth, but then 
GFRα1a takes over (Charlet-Berguerand et al., 2004). Also GFRα2 presents multiple isoforms: 
GFRα2a is the full-length isoform, GFRα2b lacks D1, and GFRα2c has the same sequence as 
GFRα2b, but lacks the first 28 residues after the signal sequence (Wong and Too, 1998). It has 
also been suggested that GFRα4 generates a GPI-anchored, a transmembrane, and a soluble iso-
form (Lindahl et al., 2000, Lindahl et al., 2001). 
 
3.2 Rearranged during transfection (RET) 
A mutated form of RET was first identified in human lymphoma (Takahashi et al., 1985), 
while its role in GFL signalling was discovered only 11 years later (Durbec et al., 1996, Trupp et 
al., 1996). Even though GFLs do not bind RET directly, this receptor is fundamental for signal 
transduction inside the cell. RET is heavily N-glycosylated and composed by four cadherin-like 
domains (CLD1-4), one Cys-rich domain, a transmembrane region and an intracellular part with 
a tyrosine kinase domain. The region between CLD2 and CLD3 binds a calcium-ion (Ca2+) that is 
thought to stabilize the complex as it enables CLD1 to take contact with the ligand once the GFL 
has bound its GFRα co-receptor (Anders et al., 2001). In addition to CLD1, also CLD2 and 
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CLD3 have been shown to be important for binding to the GFL-GFRα complex (Kjær and Ibáñez, 
2003), and likewise CLD4 and the Cys-rich domain play a role (Amoresano et al., 2006). The 
current hypothesis is that most C-terminal parts of the extracellular domain are important for 
taking direct contact with the GFL-GFRα complex, while CLD1-2 form a structure that stabilizes 
the complex (Kjær et al., 2010). The glycosylation level of RET does not seem to affect its bind-
ing to GFL-GFRα (Kjær and Ibáñez, 2003). 
The transmembrane domain of RET is important for association of the dimer, and there-
by for intracellular signalling (Kjær et al., 2006). The intracellular part of RET is composed of a 
juxtamembrane domain, a tyrosine kinase domain, and a C-terminal tail. The juxtamembrane 
domain contains tyrosine and serine residues (Tyr687 and Ser696) which are important for cyclic 
adenosine monophosphate (cAMP)-mediated modulation of RET activity (Liu et al., 1996). In-
deed, mutation of Ser696 leads to defects in migration of enteric neurons (Asai et al., 2006). The 
kinase domain harbours several Tyr residues, and the C-terminal tail has different lengths, de-
pending on the RET splice variant. The most studied splice variants are RET9 and RET51, which 
have identical N-termini. However, their C-terminal extensions starting at residue 1064 have 
different lengths and contain different residues. RET9 has a shorter extension of 9 amino acids, 
which are different from those present in the longer extension of 51 amino acids present in 
RET51 (Tahira et al., 1990). There is also a variant of RET with 43 C-terminal residues, and 
many more could exist based on analysis of DNA and RNA sequences (Myers et al., 1995). 
Upon formation of the GFL-GFRα-RET dimeric complex, the intracellular domain of 
dimeric RET gets transautophosphorylated and initiates the signalling cascade inside the cell. 
There are several Tyr residues that can become phosphorylated, each of them with a different role. 
At the moment the most studied are Tyr 687 (located in the juxtamembrane domain), 900, 905, 
981, 1015, 1062, and 1096 (Figure 6). In addition to its role in cAMP-mediated modulation of 
RET activity (see above), Tyr687 has been shown to recruit the tyrosine-protein phosphatase non-
receptor type 11 (SHP2) and to be involved in mediating GDNF activity; however, for SHP2 to 
have effect, also the complex docked on Tyr1062 is essential (Perrinjaquet et al., 2010). It has been 
shown that both residues located in the catalytic site (Tyr900 and Tyr905) are phosphorylated upon 
ligand binding, however, Tyr905 is the most important for downstream signalling (Kawamoto et 
al., 2004). Tyr905 is also the binding site of the growth factor receptor-bound protein 7 (Grb7) and 
10 (Grb10, Pandey et al., 1996). Tyr981 binds the proto-oncogene tyrosine-protein kinase Src, 
thereby promoting GDNF-induced survival (Encinas et al., 2004). Tyr1015 binds PLCγ, and its 
mutation leads to decreased RET signalling and reduced oncogenic activity of the mutated form 
of RET formed by chromosomal rearrangements (Borrello et al., 1996). Tyr1062 can bind both Src 
homology 2 domain-containing protein (Shc) and the fibroblast growth factor receptor substrate 2 
(FRS2) proteins (Asai et al., 1996), thus activating either the RAS/ERK (rat sarcoma and extra-
cellular signal-regulated kinase, respectively) pathway and the PI-3-K/AKT (phosphoinositide 3-
kinase and protein kinase B, respectively) pathway (Kurokawa et al., 2001), or the recruitment of 
Grb2 (Scott et al., 2005). Tyr1062 can bind also Dok proteins, leading for instance to neurite out-
growth in PC-12 cells (Grimm et al., 2001), and Enigma, causing mitogenic signalling, but the 
tethering of this last factor does not depend on phosphorylation (Durick et al., 1996). Tyr1096 
binds Grb2, and a mutation of this residue is involved in the activity of the oncogenic form of 
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RET involved in multiple endocrine neuroplasia (MEN) 2B (Liu et al., 1996). Note that because 
of the different lengths of the isoforms, this last Tyr residue is present only in RET51. This is 
thought to be the reason why RET51 is degraded more rapidly than RET9 (Scott et al., 2005): it 
has two Tyr that can bind (directly or indirectly) Grb2, which associates with Cbl and is promot-
ing ubiquitynation and subsequent degradation of RET. 
 
Figure 6. Schematic representation of the messenger 
proteins bound by the different tyrosines of the RET 
intracellular domain. The dark grey square represents the 
juxtamembrane domain, the light grey rectangle represents 
the tyrosine kinase domain, and its shaded part containing 
the residue 1096 is present only in the longer RET isoform 
(RET51). SHP2-mediated signalling requires interaction 
with complexes docked on residue 1062 (broken line). 
Abbreviations: AKT: protein kinase B, ERK: extracellular 
signal-regulated kinase, Grb: growth factor receptor-bound 
protein, PI-3-K: phosphoinositide 3-kinase, PLCγ: phos-
pholipase C gamma, RAS: rat sarcoma, RET: rearranged 
during transfection, Ser: serine, Shc: Src homology 2 do-
main-containing protein, SHP2: tyrosine-protein phospha-
tase non-receptor type 11, Src: proto-oncogene tyrosine-
protein kinase, Tyr: tyrosine. 
 
After activation, the receptor complex is internalized through the sortilin-related receptor 
SorLA. The internalization directs GDNF to the lysosomes and GFRα1 to the recycling pathway. 
SorLA also plays a role in the internalization of RET when GFRα1 is present, but this occurs 
independently of GDNF. The fate of RET has not been investigated in detail, but the internaliza-
tion through SorLA does not seems to lead to increased RET degradation (Glerup et al., 2013). 
GDNF and RET are known to be retrogradely transported in neurons (Coulpier and Ibáñez, 2004, 
Tsui and Pierchala, 2010), but the internalization in this case is not due to SorLA, which is not 
present at the axon terminal (Glerup et al., 2013). Internalization of RET is not only important for 
regulating the amount of available receptor on the cell surface, but also for signalling: ERK is 
activated only if RET is internalized, while the AKT pathway can be activated when the receptor 
is on the cell surface. Activation of ERK has been linked to cell survival and proliferation, while 
activation of AKT is involved in cell survival and differentiation (Richardson et al., 2006). 
RET signalling is also regulated by the growth-arrest specific protein (Gas1). This pro-
tein shows sequence similarity with the GFRα co-receptors s and inhibits GDNF signalling: RET 
binding to Gas1 precludes subsequent GFRα1 binding to RET. This prevents RET phosphoryla-
tion and AKT-mediated signalling (Cabrera et al., 2006). The same protein enhances Sonic 
hedgehog (Shh) signalling, and it has been shown that Gas1 mutants have deficits in the gastroin-
testinal system due to reduced Shh signalling and enhanced RET signalling (Biau et al., 2013). 
RET is expressed in many different cell types. These include dopaminergic, noradrener-
gic and motor neurons, sympathetic, parasympathetic and sensory neurons, and the ENS. RET 
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mostly regulates the growth and maturation of these structures, and it is important for mainte-
nance of dopaminergic neurons: conditional knock-out mice do not show degeneration at nine 
months of age (Jain et al., 2006), but at two years the amount of dopaminergic neurons is signifi-
cantly reduced compared to wild-type mice (Kramer et al., 2007). Homozygous knock-down of 
RET is lethal in mice (Schuchardt et al., 1994). These mice die soon after birth due to kidney 
agenesis and lack of enteric neurons, a phenotype that resembles closely those of GDNF and 
GFRα1 knock-outs. This effect is isoform-dependent: mice lacking RET51 develop normally and 
do not present any obvious phenotype, but when RET9 is not present the enteric ganglia are miss-
ing from the colon and kidneys are small and underdeveloped (de Graaff et al., 2001). 
Outside the nervous system, RET can be found for instance in ureteric buds, spermatogo-
nia, and thyroid (Wang, 2013). This receptor is implicated in various diseases: it is constitutively 
active in patients affected by tumours of neural crest origin, such as neuroblastoma, pheochromo-
cytoma, and medullary thyroid carcinoma (MTC), which affects the calcitonin-producing C cells 
in the thyroid. These conditions can be present alone, for instance in familial medullary thyroid 
carcinoma (FMTC) only MTC is present, or together with others, like in MEN syndromes. 
MEN2A patients show MTC, pheocromocytoma and hyperparathyroidism, while MEN2B pa-
tients display MTC, pheochromocytoma, marfanoid habitus, thickened corneal nerve, and gan-
glioneuromatosis of gastrointestinal tract (Santoro et al., 2004). In these cases the gain-of-
function mutations are usually, but not always, located in the Cys-rich or in the kinase domain 
and lead to constitutive receptor dimerization and/or signalling (see for instance Takahashi et al., 
1998, Iwashita et al., 1999). Another type of tumour where RET is constitutively active is papil-
lary thyroid carcinoma: in this case RET gene is rearranged so that it is fused with heterologous 
genes (Arighi et al., 2005). On the contrary, in patients with Hirchsprung’s disease, RET presents 
mutations that make it inactive and cause lack of neurons in the distal segments of the ENS 
(Arighi et al., 2005). In this case, many mutations occur on the CLDs, and they affect the folding 
of the molecule, its maturation and the transport to the cell membrane (for a list of references see 
Anders et al., 2001). Other relevant residues are located in the kinase domain or important for 
binding adaptor proteins (Iwashita et al., 1996, Geneste et al., 1999). For more comprehensive 
reviews about RET signalling and role in diseases, see Arighi et al., 2005 and Runeberg-Roos 
and Saarma, 2007. 
 
3.3 Role of the neural-cell adhesion molecule (N-CAM) in GFL signalling 
N-CAM is a neural cell adhesion molecule identified almost 40 years ago in neural reti-
nas of chick embryo (Thiery et al., 1977). Besides cell-cell adhesion, it can mediate many other 
processes, including cell-matrix adhesion, neurite outgrowth, neuron-muscle interaction, synapse 
formation and synaptic efficacy. In addition, N-CAM expression is elevated in certain tumours, 
including small cell lung cancer, neuroblastoma, and rhabdomyosarcoma. Despite N-CAM being 
expressed both in tumours and in tissues surrounding them, research has focused on immunother-
apeutic targeting of N-CAM (Jensen and Berthold, 2007). N-CAM interacts with several different 
ligands (Jensen and Berthold, 2007), but this paragraph will briefly deal with its role in GFLs 
signalling.  
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There are several N-CAM isoforms, but the most studied have differences only in the C-
terminal part. N-CAM120 is GPI-anchored, N-CAM140 has a short intracellular domain, and N-
CAM180 has a long intracellular domain (Dallerác et al., 2013). N-CAM120 and N-CAM140 
have been shown to bind GFRα1 and GDNF. In the presence of GDNF and GFRα1, N-CAM140 
is able to initiate signalling inside the cell independently of RET. Binding to N-CAM leads to 
reduced N-CAM-mediated adhesion, to Schwann cell migration and to axonal growth in neurons 
located in the cortex and hippocampus, and occurs via phosphorylation of the proto-oncogene 
tyrosine-protein kinase Fyn and the focal adhesion kinase (FAK), which participate in rear-
rangements of the cytoskeleton. N-CAM can be polysialylated (PSA), leading to an increased 
negative charge. PSA-N-CAM binds GDNF directly, but for signalling the presence of GFRα1 is 
required (Paratcha et al., 2003). Evidence suggests that also the other GFLs in complex with their 
respective GFRα co-receptors can signal through N-CAM independently of RET. For instance, it 
has been shown that GDNF, NRTN and ARTN induce increased release of calcitonin gene-
related peptide (CGRP) in sensory neurons in the presence of capsaicin. Intriguingly, when 
knocking-down the expression of RET (Schmutlzer et al., 2011), GDNF-induced increase is es-
sentially abolished, but the effects of NRTN and ARTN are only reduced. Further decrease is 
observed when also N-CAM expression is knocked-down, suggesting that NRTN and ARTN 
signalling is mediated not only by RET but also by N-CAM (Schmutlzer et al., 2011). In addition, 
at least upon overexpression, N-CAM can bind GFRα4, suggesting that also PSPN could signal 
through this alternative pathway (Paratcha et al., 2003). 
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4. Glycosaminoglycans (GAGs): roles in GFL signalling 
 Glycosaminoglycans (GAGs) are long linear polysaccharides composed of two repeating 
sugars. These sugars are usually an amino sugar, like N-acetylglucosamine (GlcNAc) or N-
acetylgalactosamine, galactose (Gal) or an uronic sugar (glucuronic acid, GlcA, or iduronic acid, 
IdoA). GAGs are divided into four groups, based on core disaccharide sugars: hyaluronic acid 
(HA), keratan sulphates (KS), chondroitin/dermatan sulphates (CS), and HS. GAGs can be 
transmembrane, GPI-anchored to the cellular membrane, or soluble proteins. Several types of 
GAGs can be linked to the same protein, for instance syndecan-3 contains both HS and CS side 
chains (Bovolenta and Fernaud-Espinosa, 2000). GAGs are usually synthesized in the Golgi, 
except for HA which is synthesized at the cellular membrane (Fraser et al., 1997). This is in ac-
cordance with the fact that HA is the only GAG present not only in mammalian cells, but also in 
bacteria, which do not have organelles, and therefore have to rely on different mechanisms for the 
synthesis of GAGs. All GAGs are highly polar, but HS, CS and KS are rich in sulphate groups 
(which are heavily negatively charged), while HA is not sulphated (Bovolenta and Fernaud-
Espinosa, 2000).  
GAGs can bind many different types of proteins, such as proteases and their inhibitors, 
chemokines, cytokines, and growth factors. As an example, heparin alone interacts with almost 
one fourth of the plasma proteins. GAGs are also components of the extracellular matrix (ECM), 
and can bind other macromolecules of the ECM. As the ECM provides structural and biochemi-
cal support to the cells, GAGs have for instance roles in cell adhesion, cell-to-cell communica-
tion, and differentiation. GAGs have also other physiological roles, including ligand binding, 
signalling regulation, and protection from proteolytic cleavage (Zhang, 2010). 
It is not known whether GFLs bind HA or KS. Therefore the next paragraphs will present 
only chondroitin/dermatan sulphate proteoglycans (CSPGs) and HSPGs, particularly syndecan-3. 
CSs and HSs are produced in huge amounts by the cells. Their exact amounts and types vary 
based on the tissue, but each cell exposes 105-106 molecules on its surface, and their concentra-
tion in the ECM is in the range of mg/ml. CS and HS can be attached to proteins, forming CSPGs 
and HSPGs, but also hybrid proteoglycans. Each proteoglycan can host from one to more than 
hundred GAGs (Zhang, 2010). 
 
4.1 Chondroitin/dermatan sulphate proteoglycans (CSPGs) 
 CSPGs are formed through a series of enzymatic steps (Zhang, 2010) which starts with 
the addition of a linker tetrasaccharide to a Ser residue in the sequence Ser-Gly/Ala-X-Gly 
(where X is not Pro). This link is composed of GlcA-Gal-Gal-Xyl, and the first sugar to be added 
in the endoplasmic reticulum is xylose (Xyl). Until this point, syntheses of CS and HS are identi-
cal, but the moiety of the fifth sugar determines what type of GAG will be formed. In the case of 
CS, N-acetylgalactosaminyltransferase I adds N-acetylgalactosamine (GalNAc), and then chon-
droitin synthase attaches GlcA and GalNAc. These form the repeating disaccharide typical of 
most CS except dermatan sulphate, where GlcA is replaced by IdoA (Figure 7A). 
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Figure 7. A. Synthesis of CS. In dermatan sulphate, the GlcA of the repeating disaccharide unit is replaced 
by IdoA. B. Synthesis of HS. Yellow: Xyl, green: Gal, light blue: GlcA, red: GalNAc, lilac: GlcNAc.  
 
The sugar structure is then sulphated: CS have long tracts consisting of modified disac-
charides. Some types of sulphation are present both in CS and HS, but others are specific for each 
type: for instance only CSs present GlcA-3-O-sulphation. Other modifications consist in 4-O- 
and 6-O-sulphation of GalNAc, and 2-O-sulphation of the uronic acid (Zhang, 2010). 
 CSs are typically involved in structural and regulatory activities. For instance, as compo-
nents of the ECM, they are important for the integrity of tissues like cartilage (Dijkgraaf et al., 
1995). In the CNS, CS have a regulatory role: they are for instance the fundamental components 
of the perineuronal nets (PNNs) in the brain and in the visual cortex. PNNs are specialized struc-
tures of the ECM which have a role in the closure of critical periods. During the critical period, 
sensory experience shapes the organization of the neuronal network, which is plastic at this stage. 
For example, in the visual cortex of young rats the PNN is not completely formed: this allows 
plasticity and correct organization of the neuronal connections. However, the cortex of adult rats 
with a well-developed PNN is less plastic. This is partially due to CSPGs which are present in 
adult rats, but not in younger animals. It has been shown that digestion of CSPGs with chon-
droitinase ABC restores the neuronal plasticity in adults (Pizzorusso et al., 2002). However, some 
CS have apparently different functions: a class of CS (CS-E) is instead promoting axonal growth 
in a cell-specific fashion (Mikami and Kitagawa, 2013). 
GDNF binds CS with high affinity (10-fold higher than affinity to HS) and with almost 
no dissociation. It has therefore been proposed that CS could keep holding neurotrophic factors 
while presenting it to the receptor, or that growth factors could be enzymatically released from 
such molecules (Nandini et al., 2004). However, CS does not seem to be important for GDNF 
signalling, as this is not decreased in cells lacking CSPGs, and exogenously added CS had only a 
slight effect on GDNF activity (Barnett et al., 2002). 
 
4.2 Heparan sulphate proteoglycans (HSPGs) 
Synthesis of HSPGs starts in the same way as that of CSPGs. The difference arises when 
the fifth sugar is added to the linker sequence: in the case of HSs this is GlcNAc, and the repeat-
           A                                             B 
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ing disaccharide unit is composed by GlcA and GlcNAc (Figure 7B), added respectively by exos-
tosin I and II (Zhang, 2010).  
Differently from CS, HS present long streaks of non-sulphated disaccharides separating 
clusters of modified sugars. Like CS, HS can be O-sulphated, but only CS can be modified with 
N-sulphation (Zhang, 2010). HSPGs can be roughly divided in three main groups: syndecans 
have transmembrane domains and interact with intracellular proteins, glyphicans are GPI-
anchored, and other HSPGs (for instance perlecan, agrin, and collagen XVIII) are secreted, 
ECM-located proteins (Lindahl and Kjellén, 2013). 
Because of the presence of sulphate groups, HS are highly negatively charged and can 
bind several types of molecules, including growth factors, morphogens and inflammatory media-
tors (Lindahl and Kjellén, 2013). They have therefore many different functions: form protein 
gradients, protect molecules from degradation, have structural roles, and are implicated in signal-
ling, either directly or because they affect the binding of ligands to their receptors. Dysregulation 
of this last function has been observed in several pathologies. For instance HS-dependent Wnt 
signalling is upregulated in gastric cancer (Takei et al., 2011), and HSPG-related bone morpho-
genetic protein (BMP) signalling is involved in fibrodysplasia ossificans progressiva (O’Connell 
et al., 2007). 
Regarding binding to GFLs, it is known that GDNF, NRTN, and ARTN, but not PSPN, 
have high affinity for heparin and HS (Alfano et al., 2007, Bespalov et al., 2011), and that the 
same is true at least for GFRα1 (Parkash et al., 2008). It has therefore been proposed that HSPGs 
are important for GFL signalling, and this has been shown both for HS (Barnett et al., 2002, Pil-
tonen et al., 2009) and heparin (Tanaka et al., 2002). GDNF binding to HS depends on the 2-O- 
and the 6-O-sulphation of HSPGs (Rider, 2003, Bespalov et al., 2011). This is also reflected by 
the fact that the phenotype of mice lacking 2-O-sulphotransferases resembles closely that of 
GDNF, GFRα1 or RET knock-outs: the animals die perinatally because they lack kidneys. This is 
caused by failure of ureteric bud branching and condensation of the mesenchyme. These mice 
also show ocular and skeletal defects (Bullock et al., 1998). SULF1 and SULF2 are extracellular 
enzymes which remove 6-O-sulphation from HS. Mice with double knock-out of these enzymes 
have an increased GDNF binding to HS and reduced signalling in the embryonic oesophagus. As 
SULFs are differentially expressed, they could be important to regulate GDNF binding and sub-
sequent activity in different tissues during development (Ai et al., 2007). Moreover, HSPGs may 
not only regulate GDNF access to GFRα co-receptors, but can themselves act as signalling recep-
tors for the molecule. This is the case for syndecan-3 which has been shown to bind immobilized 
GDNF and stimulate cell spreading and neurite outgrowth via the Src family kinase (SFK). 
ECM-bound GDNF is therefore thought to be involved in cell migration during the development 
of the cortex (Bespalov et al., 2011). 
Knock-out and/or mutation of different types of HSPGs have been performed in mice 
models. The effects range from not noticeable phenotypes to early embryonic death, with the 
most severe phenotypes appearing when HS chains are lost (Lindahl and Kjellén, 2013). Howev-
er, not much is known about the role of HSPGs in PD and whether their expression is somehow 
altered in patients. Only one study has focused on the role of agrin, a transmembrane and extra-
cellular HSPG, in PD. This study shows that agrin binds α-synuclein, promoting conformational 
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changes and aggregation, and reducing its solubility. In the same study, agrin was found to colo-
calize with Lewy bodies in the substantia nigra of PD patients (Liu et al., 2005). As Lewy bodies 
are located intracellularly, it would be interesting to understand whether this is due to alterations 
in agrin trafficking or endocytosis. Another study has focused on the matrix metalloproteases, 
enzymes which degrade the ECM and are released by several cell types in the CNS in response to 
cytokines and oxygen-free radicals. Results showed increased amounts of matrix metalloprotease 
inhibitors in the substantia nigra and cerebrospinal fluid of PD patients (Lorenzl et al., 2003). The 
authors hypothesize that the increased levels of inhibitors would prevent further damage to the 
ECM, but do not comment on the possible effects on the level of ECM proteoglycans. 
 
4.2.1 Syndecan-3 
 Syndecans are transmembrane HSPGs. They are divided into several families, of which 
syndecan-3, also known as N-syndecan, has been shown to be important for GDNF signalling. 
Syndecan-3 (Carey et al., 1992, Gould et al., 1992) has an extracellular domain which harbours 
several GAGs. Syndecans have variable N-termini which are followed by more conserved se-
quences including a cleavage site and the transmembrane and cytoplasmic domains (Bernfield et 
al., 1992).  
Syndecans are present in all tissues, but with a very specific distribution: for instance 
syndecan-3 is mostly found in neurons (Carey et al., 1992). Homozygous syndecan-3 knock-out 
mice are viable, but present altered feeding behaviour (Reizes et al., 2001), higher long-term 
potentiation in the hippocampus with subsequent hippocampal memory impairment (Kaksonen et 
al., 2002), and impaired cell migration (Hienola et al., 2006).  
Like all other HSPGs, one of the roles of syndecans is to bind ligands so that they can 
then be presented to their receptors. One example of such a function of syndecan-3 is related to 
feeding behaviour. Anti-satiety molecules, like the agouti-related peptide (AGRP), and satiety 
ones, as the α-melanocyte stimulating hormone (α-MSH), compete for binding to the same recep-
tor (melanocortin-3/4 receptor). Syndecan-3 can bind AGRP, thus enhancing its interaction with 
this receptor and increasing hunger. However, when the extracellular domain of syndecan-3 is 
cleaved in response to feeding, also AGRP is removed, so that α-MSH can bind the receptor and 
mediate satiety (Reizes et al., 2001). 
However, syndecans do not only participate in ligand-receptor interactions, but due to 
their intracellular domain can also activate different signalling pathways inside the cell, like the 
protein kinase C alpha (PKCα, Lebakken and Rapraeger, 1996), and SFK (Kinnunen et al., 1998). 
The way the signalling starts is not very well known, but it is thought that ligand binding triggers 
syndecan oligomerization/clustering. This has been proposed, for instance, in the case of the hep-
arin-binding growth associated molecule (HB-GAM)-induced syndecan-3 activation (Rauvala et 
al., 2000). Syndecan-3 binding of immobilized (but not free) HB-GAM induces neurite out-
growth and cell spreading. This happens via SFK, which promotes activation of factors responsi-
ble for actin branching. As syndecans do not have tyrosine kinase or any other catalytic activity, 
it is thought that their oligomerization brings the signalling complexes bound to the cytoplasmic 
domain of syndecans close together. This proximity promotes transactivation of the downstream 
signalling effectors. (Raulo et al., 1994, Kinnunen et al., 1998).  
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Syndecan-3 may both help GFL-receptor interaction and act as a GFL receptor itself. 
Syndecans bind several different cell-adhesion molecules, such as N-CAM (Storms and Rut-
ishauser, 1998). It is known that GDNF binds syndecan-3 (Bespalov et al., 2011), and N-CAM 
(Paratcha et al., 2003). Therefore, it is tempting to speculate that syndecan-3 in this case presents 
GDNF to N-CAM and facilitates their interaction. Moreover, it has been shown that immobilized 
GDNF, NRTN, and ARTN bind syndecan-3 and promote cellular migration and neurite out-
growth by activating Src kinase. This suggests a role of ECM-bound GFLs in brain development, 
and is supported by the observation that both GDNF and syndecan-3 knock-out mice have fewer 
cortical γ-aminobutyric acid–releasing neurons (Bespalov et al., 2011).  
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5. Neurotrophic factors as PD therapeutics: focus on GDNF and NRTN 
Delivery of neurotrophic factors is considered to be the most promising direction at the 
moment. There are several reasons for this: first, many of these factors have been shown to pro-
mote neuron survival and regeneration in toxin-induced models of PD. Second, neurotrophic 
factors could also be useful in restoring the functions of neurons which are losing their phenotype 
(Peterson and Nutt, 2008). It has also been proposed that degeneration of dopaminergic neurons 
could be due to the loss of these neurotrophic factors or impairment of their signalling (Granholm 
et al., 2000, Kramer et al., 2007). All these arguments support the hypothesis that trophic factor 
delivery would restore signalling pathways and therefore stop or slow down neuronal degenera-
tion. Delivery can occur in different ways: for instance as purified protein, through lentivirus or 
adeno-associated viruses (AAV), or via encapsulated cells secreting the factor. GDNF and NRTN 
have been used in clinical trials (see sections 5.1-3) and delivered as protein and via AAV2 vec-
tors, respectively. The use of encapsulated, rather than naked, cells for delivering GDNF prevents 
migration of the cells to other structures and the risk of rejection. The techniques used to produce 
encapsulated cells have improved with time, but still the production of GDNF decreases when the 
cells are implanted in vivo, so this technique requires better development before it can be used in 
clinical trials (Lindvall and Wahlberg, 2008).  
 
5.1 Therapeutic potential of GDNF protein delivery 
Recombinant methionine human GDNF (also called liatermin or r-metHuGDNF) entered 
PD clinical trials more than ten years ago (Gill et al., 2003). This factor was produced in E. coli 
by Amgen and had the sequence of mature GDNF with an extra methionine at the N-terminus. 
Liatermin was used in all the listed clinical trials where GDNF was delivered as a protein (Table 
2). 
As GDNF does not pass the BBB, it had to be injected directly into the brain tissue of pa-
tients. Since data available from animal models (Gash et al., 1998) had showed that GDNF was 
effective when injected intraventricularly, intrastriatally, and intranigrally, the first Phase 1/2 trial 
(Nutt et al., 2003) relied on those results. GDNF was delivered into the right ventricle of PD pa-
tients. The subjects received monthly injections of either placebo or GDNF (ranging from 25 to 
4000 µg) for eight months in a double-blind study. Part of them entered then an open-label trial. 
All patients receiving GDNF showed adverse effects like loss of appetite, nausea, depression, and 
Lhermitte’s sign (an electrical sensation running down the spine and limbs), and none improved 
significantly when compared to patients treated with placebo. One of the GDNF-treated patients 
died three weeks after receiving the last injection, of causes unrelated to the treatment. His brain 
was fixed and analysed (Kordower et al., 1999). Results showed that TH levels in the striatum 
were not different from those of PD controls who had not received GDNF treatment, but they 
were elevated in a region going from the bed nucleus of the stria terminalis to the substantia 
innominata. In addition, no GDNF immunoreactivity was observed in the treated patient, while 
the growth factor was detectable, although in low amounts, in a monkey MPTP-model which had 
received GDNF injections and was used as a control in the same study (Kordower et al., 1999). 
The authors conclude that the presence of the adverse effects showed that GDNF was biological-
ly active, but the protein had failed to reach the putamen and the SNpc, probably due to the large 
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brain volume (Kordower et al., 1999, Nutt et al., 2003). However, GDNF was administered to the 
monkeys following a different protocol, and the time between the last GDNF injection and the 
diffusion analysis was much shorter in the animals than in the deceased patient. Therefore the 
results remain unclear. 
Meanwhile, GDNF injected into the striatum of a primate model of PD had been shown 
to be retrogradely transported along the dopaminergic axon terminals and to promote the survival 
of dopaminergic neurons (Grondin et al., 2002). Following these findings, another Phase 1 clini-
cal trial (Gill et al., 2003) was started. In this case 14.4 µg/side/day of r-metHuGDNF was chron-
ically infused for two months into the striatum of five PD patients through a catheter connected to 
a pump. After this time, the daily dose of GDNF was increased to 43.2 μg/side/day. One of the 
patients had unilateral symptoms and received the protein only on the contralateral side; the oth-
ers were affected bilaterally, and received GDNF on both sides. This time, the only adverse effect 
was the Lhermitte's sign. In addition a region of high signal was visualized close to the catheter 
tip during magnetic resonance imaging (MRI). Its intensity varied between patients (and hemi-
spheres), but was stronger at higher doses of GDNF, so the amount of neurotrophic factor inject-
ed was reduced back to 14.4 µg/side/day, as the clinicians hypothesized that the signal could be 
due to oedema or protein accumulation. The results were positive: PD symptoms improved after 
three months of infusions, to the point that there were no periods of severe immobility anymore 
and some patients were more responsive to L-DOPA, so they could reduce the dosage of medi-
cine. In addition, three patients out of five recovered the sense of smell, which is often impaired 
in PD. The scores on the Unified Parkinson's Disease Rating Scale (UPDRS, a scale where be-
haviour, mood and clinical symptoms are evaluated by the clinician, and the patient self-
evaluates several activities of daily life which range from swallowing to hygiene) were 48% low-
er than the baseline after one year of treatment. Also the sub-scores measured during daily activi-
ties had improved. At the same time, the uptake of 18F-DOPA in the putamen and the SNpc was 
increased (Gill et al., 2003). 
A two-year follow-up (Patel et al., 2005) showed that patients could tolerate continuous 
GDNF infusions over a long period, and that the molecule was effective in slowing down the 
progression of the disease. Moreover, when the patient that had received only unilateral injection 
died of unrelated causes, analysis showed that GDNF had induced increase in TH nerve fibres in 
the striatum and, possibly, also sprouting of fibres in the SNpc (Love et al., 2005). 
The patients treated in this study were only a few, without negative control, and in addi-
tion it is known that a certain improvement is seen also in patients treated with placebo (Goetz et 
al., 2000). Nevertheless the improvement was so noticeable, that it was decided to verify the 
results with a Phase 2 trial (Lang et al., 2006). This time, 34 patients were bilaterally implanted 
with the catheter and randomly divided into two groups, of which one was treated with placebo 
and the other with GDNF (continuous infusion for a total of 15 µg/side/day). Unfortunately, the 
results were not as good as in the Phase 1 trial: patients treated with GDNF did not develop seri-
ous side effects (only headaches, paresthesias and upper respiratory tract infections were report-
ed), but their condition did not improve either. In addition, some of the patients developed 
GDNF-neutralizing antibodies, but these did not give rise to further consequences. The authors 
hypothesize that the discrepancies were probably due to a placebo effect, with patients improving 
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more in the Phase 1 study (Gill et al., 2003) because they had higher expectations. Other reasons 
could have been the differences in dosage, in the condition of the patients (those participating in 
the Phase 1 trial had milder PD and therefore their neurons could have been more responsive) and 
in the catheter used, as the one adopted during the Phase 2 trial was smaller. 
Meanwhile, another Phase 1 trial (Slevin et al., 2005) with a different protocol was being 
carried out. In this case, the catheter was inserted only controlaterally to the most affected side. 
The other difference between this trial and the previous one (Gill et al., 2003, with its continua-
tion into Phase 2, Lang et al., 2006) was the delivery method, which was implemented with the 
goal of enhancing GDNF diffusion. They used a multiport catheter, and the protein was infused 
using a convection-enhanced delivery-like fashion (CED). CED-like delivery was obtained by 
continuous infusion at 2 µl/hour, plus small bolus injections every six hours. Ten patients receive 
daily doses of GDNF which were increased at eight-week intervals (starting from 3 µg/day and 
up to 30 µg/day), and the results were evaluated one month after the last injection. Again, the 
only observed side effect was Lhermitte's sign, and the patients improved significantly on both 
sides, showing for instance a better posture and speech than prior to the therapy. However, while 
the extended part of the trial was ongoing, Amgen decided to halt all the ongoing trials, due to the 
failure of the Phase 2 trial and to safety issues (Lang et al., 2006). The safety issues included the 
already mentioned development of GDNF-neutralizing antibodies by some of the patients (prob-
ably due to peripheral leakage), and cellular damage occurring in certain brain areas. It was later 
hypothesized (Salvatore et al., 2006, Slevin et al., 2007) that the damage could depend on the 
sudden GDNF withdrawal: delivery of exogenous GDNF could downregulate synthesis of en-
dogenous protein, so that, after stopping the therapy, GDNF-dependent cells would die because 
of lack of neurotrophic factor. One year after the termination of the study, patients that had par-
ticipated in the trial by Slevin et al were analysed again (Slevin et al., 2007): results showed that 
all the improvements were lost. This led the authors to conclude that continuous GDNF infusion 
is necessary to maintain the positive effects. In addition, they discuss the results of the Phase 2 
trial conducted by Lang and colleagues, pointing out that the antibodies developed by some of the 
patients were against exogenously added recombinant GDNF (produced in E. coli and then re-
constituted), and therefore not necessarily effective against endogenous GDNF. 
These were not the only critiques to the Phase 2 study (Lang et al., 2006): Hutchinson et 
al (2007) reported that the standard deviation of the measurements was much higher than ex-
pected. Therefore the study was underpowered, and the results inconclusive. Moreover, a study 
by Salvatore et al (2006) used the same delivery system and protocol as in the failed Phase 2 trial 
to study the diffusion of 125I-GDNF in monkey brains. GDNF was detected by measuring iodine 
signal, by immunohistochemistry and by enzyme-linked immunosorbent assay (ELISA): the re-
sults showed that GDNF was present in the putamen and retrogradely transported to the SNpc, 
but its concentration and volume of diffusion varied greatly between monkeys. The highest con-
centration of GDNF was found within a 2-mm distance from the catheter tip, and the diffusion 
volume ranged between 87 and 369 mm3, enough to cover only from 2 to 9% of the human pu-
tamen (4-5000 mm3, as reported in Salvatore et al., 2006). This volume is much smaller than 
those achieved with other infusion methods, such as the use of multiport catheters and CED, and 
this could therefore explain why the Phase 2 trial (Lang et al., 2006) failed. 
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5.2 Therapeutic potential of virally-delivered NRTN 
Research turned to viral delivery of trophic factors, especially via AAV2. Viral vectors 
have several advantages. First, one injection is sufficient to induce expression of the encoded 
protein for up to several years (Bankiewicz, 2004). Second, the use of viral vectors ensures that 
the protein is produced in the patient’s cells, and it has been shown that, at least in some cases, 
mammalian-produced neurotrophic factors are of better quality than recombinant factors pro-
duced in E. coli cells (Hoane et al., 2000). Ceregene developed CERE-120, an AAV2-derived 
vector encoding human NRTN where the prosequence was replaced by that of human NGF in 
order to improve NRTN secretion (Fjord-Larsen et al., 2005). CERE-120 was used in all clinical 
trials where NRTN was delivered by viral vectors (Table 3). The preclinical study (Gasmi et al., 
2007) on a rat model of PD showed that NRTN was active and that the protein and some of the 
vector were retrogradely transported to the SNpc (Kaspar et al., 2002, Gasmi et al., 2007). After 
successful trials in a monkey model of PD (Kordower et al., 2006), CERE-120 was tested in a 
Phase 1 clinical trial (Marks et al., 2008). In this trial, six patients received low dose of vector 
(1.3x1011 vg) and six a higher dose (5.4x1011 vg) injected bilaterally to their putamen: no-one 
developed serious adverse events, and even if some patients had increased amount of anti-AAV2 
antibodies in the serum, this was asymptomatic and the level decreased after six months. After 
one year of treatment, patients’ conditions had improved significantly in both groups, except in 
one case that was later diagnosed as having multiple system atrophy and not PD (Marks et al., 
2008). 
A Phase 2 trial (Marks et al., 2010) was then conducted based on these results. Patients 
received either 5.4x1011 vg or sham surgery, and were then monitored every three months for one 
year, and then followed afterwards, until the last patient had finished the 12-month study. No 
improvement was seen after one year, but after 18 months there was a significant, although small, 
difference with the baseline. This delayed response (if compared to the Phase 1 trial) could be 
probably explained by a worse condition of the patients taking part in the second study. Some 
serious adverse effects occurred, but they were connected to the surgery procedure, not to the use 
of the AAV2 vector.  
Two patients receiving AAV2-NRTN died of causes unrelated to the ongoing trial, and 
their brains were analysed to gather more information about the bioavailability of NRTN (Bartus 
et al., 2010). In this study, the expression of TH and NRTN in those patients was compared to the 
expression in monkeys (young and aged control monkeys, and an adult monkey model of PD). In 
both humans and monkeys, NRTN covered 15% of the striatum, but in humans only little NRTN 
was detectable in the SNpc. This was different from what observed in monkeys: both in aged 
monkeys and in the PD model, NRTN was detectable also in the nigra, with extensive evidence 
for retrograde transport. In the same way, TH induction was observed only sparsely in the striata 
of patients and not in their nigrae, but TH signal was widely present in both structures in mon-
keys. This discrepancy suggests a difference in the retrograde transport in human PD patients 
versus animal PD models, and the authors concluded that perhaps targeting directly the SNpc (i.e. 
the dying neurons) could be more beneficial (Bartus et al., 2010). 
Since SNpc is the structure where the somata of the dying neurons are located, one could 
wonder why this area had not been targeted in any of the clinical trials conducted so far. However, 
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this had not been done because of safety concerns raised by preclinical studies where GDNF 
delivered to the nigra had induced robust weight loss in animal models (Zhang et al., 1997, 
Manfredsson et al., 2009). Further studies then showed that the weight loss was not due to deliv-
ery of the molecule to the nigra, but to its diffusion outside that area. This was due to the viral 
vector used (AAV5-GDNF), which has lower affinity than AAV2 for the HS in the ECM and 
therefore diffuses more in the brain. When AAV2-NRTN was delivered adequately, without virus 
diffusing outside the SNpc, no side effects were observed in rat and monkey models of PD 
(Bartus et al., 2011).  
This, and the results of the Phase 2 clinical trial (Marks et al., 2010), gave rise to a Phase 
1/2 trial, where CERE-120 was delivered both to the striatum and to the nigra of PD patients 
(Bartus et al., 2013). Here, six patients were divided into two groups. Both groups received the 
same dose of CERE-120 to the nigra (4.0x1011 vg), but one received a low striatal dose of the 
virus (5.4x1011 vg, as in the previous Phase 2 trial), while the other was treated with a higher dose 
(2.44x1012 vg), as the lower dose was showed to cover only 15% of the putamen. The dosage for 
the SNpc was determined by scaling up the dose used for the preclinical studies in rats and mon-
keys, taking into account the difference in the nigral volume in the different species. The subjects 
were followed for two years and did not report any serious side effect. This led to a continuation 
of the study to Phase 2b, but unfortunately there was not a significant difference between the 
CERE-120 and the sham surgery group. Nevertheless, further data analysis showed that there was 
a difference in the response to CERE-120 based on how far the disease had progressed: people 
with a milder disease progress, responded better than those with more advanced PD (Ceregene 
press release 21.05.2013). 
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5.3 Clinical trials of neurotrophic factor delivery in PD: how to improve the results? 
With time it became clear that one of the main issues with this type of therapy is the dis-
tribution of the neurotrophic factor in the brain. GDNF and NRTN have a high affinity for hepa-
rin (Alfano et al., 2007) and HS. The ECM is rich in CS and HS (see section 4 and subsections 
therein) which bind these neurotrophic factors and hinder their diffusion significantly. Indeed, co-
infusion of GDNF or NRTN with soluble heparin increases the diffusion volume of these neu-
rotrophic factors (Hamilton et al., 2001) and such approach has been patented for GDNF delivery 
(Rossomando et al., 2006). However, this solution is probably not suitable for treating humans, 
because heparin strongly increases the risk of haemorrhage (Mittal and Rabinstein, 2012). A safer 
option would be to deliver the neurotrophic factors together with heparin analogues that prevent 
their binding to the ECM but do not have the same effects of heparin on blood coagulation. A 
different approach to the diffusion problem would be to deliver GDNF/NRTN mimetics with a 
lower affinity for HS and which can cross the BBB. A method to screen for such molecules has 
been patented (Saarma et al., 2011). 
Another approach is to develop biologically active GDNF (Leung et al., 2012) and 
NRTN variants (Penn et al., 2013) with reduced or even absent affinity to heparin. In the case of 
GDNF, it is known that the part of the sequence which mediates binding to HS is in the N-
terminus (see section 2.1 and figure 4), and it is not important for binding to the GDNF receptor 
(Alfano et al., 2007). Therefore Leung and colleagues deleted this region to improve the diffu-
sion and introduced point mutations with different purposes, including reducing immunogenic 
potential and improving stability. These GDNF variants had an increased diffusion and were 
active in vitro and in in vivo models of PD. Their use in a clinical trial was announced in 2011 
(Eli Lilly Press Release, 26.04.2011), but no further public information is available. NRTN, in-
stead, does not have such a long N-terminus (see section 2.2 and figure 4). In this case, the resi-
dues responsible for binding to HS are in what is predicted to be the heel region. NRTN has not 
been crystallized, but based on the data about GDNF binding to its receptor, this sequence is not 
important for binding to the receptor (Parkash et al., 2008). Mutation of the heel region could 
therefore be optimal to improve the diffusion of the molecule (Penn et al., 2013). 
Another approach could be to use enzymes like Sulf1 and Sulf2 that remove sulphate 
groups from HS. These groups have been shown to be important for binding of GDNF (Rickard 
et al., 2003), and therefore their removal could improve the diffusion of the molecule and have 
beneficial effects in PD patients (Ai et al., 2007). Studies have shown that HS are important for 
GDNF signalling in vitro (Barnett et al., 2002) and for efficient neuroprotection in vivo (Piltonen 
et al., 2009). However, the significance of these results is still unclear, since GDNF variants with 
decreased affinity for heparin are fully active in in vitro assays (such as receptor activation and 
neurite outgrowth) and in in vivo 6-OHDA rat models of PD (Alfano et al., 2007, Leung et al., 
2012). Therefore, it is impossible to speculate whether these approaches will be effective. 
Lastly, in an effort to combine the advantage of AAV vectors with an increase in the dif-
fusion volume, a new Phase 1 clinical trial recently started. In this trial, 24 patients with PD will 
receive 4 doses of AAV2-GDNF (9x1010 vg, 3x1011 vg, 9 x1011 vg, or 3 x1012 vg). To ensure a 
bigger diffusion volume, the vector will be delivered by CED to the putamen, and patients will be 
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followed for five years to test the safety and efficacy of this method (ClinicalTrials.gov identifier: 
NCT01621581). 
Diffusion of growth factors is an important issue, but not the only one worth considering. 
Further analysis of the data obtained in the failed phase 2 AAV2-NRTN trial (Bartus et al., 2013) 
shows that the treatment had actually been effective in patients that had been diagnosed recently 
with PD. Neurons are post-mitotic cells, and neurotrophic factors cannot stimulate their division 
in the adult brain. Since neurotrophic factors can only rescue the degenerating neurons, early 
diagnosis and therapy are essential to treat the disease. Recent studies (Kordower et al., 2013) 
show that within four years from the diagnosis the loss of fibres in the putamen is virtually com-
plete. As it is beneficial to start the therapy as soon as possible to prevent irreversible neuron loss, 
it would be useful to develop methods to efficiently diagnose the disease during the presympto-
matic stage. At the moment research is focusing on tissues, blood and cerebrospinal fluid. Some 
of the molecules that are being investigated are α-synuclein, homovanillic acid (the most im-
portant catabolite of dopamine), markers of oxidative stress, and vitamin D, but at the moment 
none of these is validated and in use in routine clinical practice (for a complete review, see Sar-
acchi et al., 2013). 
In addition, patients could benefit from the combination of neurotrophic factor delivery 
and existing therapies. For instance, it has been shown that exercise increases the levels of BDNF 
in the serum. BDNF can cross the BBB, and the increased serum levels could therefore have a 
positive effect on the surviving nigral neurons (Ahlskog, 2011). In addition, BDNF and GDNF 
have been shown to promote neuron survival via different pathways (Onyango et al., 2005). 
Therefore combining exercise with GDNF delivery could have a beneficial, synergistic effect in 
PD patients. 
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AIMS OF THE STUDY 
 
The aims of this study were to further characterize the molecular and cell biological 
properties of GDNF and NRTN, and to study how the modification of their characteristics could 
beneficially influence their function in vitro and in vivo. 
 
The specific aims were: 
 to characterize how tagging and post-translational modifications of GDNF affect its pro-
cessing, activity, and stability 
 
 to produce and characterize in vitro and in vivo NRTN mutants with full biological ac-
tivity and lower affinity for heparin 
 
 to study the possible effect of reduced heparin binding on internalization and signalling 
of NRTN and its relevance in clinical settings 
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MATERIALS AND METHODS 
 
The methods used in this study are presented below. The methods I have used or partici-
pated in are marked with a *. 
 
Method Used in 
AKT phosphorylation assay  III 
Behavioural assays 
(cylinder test, amphetamine-induced rotation assay) 
II 
Binding assays II 
Cell culturing * I, II 
Cell lysates * I, III 
Cell transfection * I, II, III 
Kidney explants II 
ERK phosphorylation assay III 
GFRα affinity chromatography II 
Heparin affinity chromatography * 
II (NRTN variants),  
III (GFRα co-receptors) 
Immunocytochemistry * II 
Immunohistochemistry * II 
LI-COR assay III 
Computational modelling of NRTN  
and its heparin-binding sites 
II 
N-terminal sequencing I, II 
Partial purification of GDNF * I 
PCR mutagenesis * I, II 
Intracerebral protein injections II 
Protein stability * I, II 
Purification of NRTN * II 
RET phosphorylation assay * I, II, III 
RT-PCR (expression of GFRα1, GFRα2 and RET) II 
Sequence analysis and alignment (Clustal W2 and omega, Expasy 
prediction tools, ELM)* 
III 
Diffusion assays in vivo (immunohistochemistry and Stereo Investi-
gator platform)*  
II 
Survival of dopaminergic neurons in vitro II 
Protein production I, II 
Western blotting * I, II, III 
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RESULTS 
 
6. GDNF: processing, stability, and glycosylation 
6.1 Processing of GDNF depends on expression conditions 
Adding tags to protein sequences can be useful in many ways. For instance it enables the 
recognition of exogenously added proteins, allows the use of more sensitive detection techniques, 
and may make purification easier. However, the choice of tag and insertion site can be crucially 
important for the folding and activity of the protein. GFLs have seven conserved Cys residues, 
which are important for the folding of the molecule (Haniu et al., 1996, Eigenbroth and Gerber, 
1997). Two of these residues are located at the C-terminus of GDNF and the addition of a tag in 
this region could be detrimental for the folding of the protein. Therefore we studied how the syn-
thesis and secretion of proGDNF and mature GDNF are affected by N-terminal Flag or His tags. 
The tags were either directly attached to the protein sequence or linked through two Gly residues. 
Gly was chosen because of its small size and flexibility (I: Table 1).  
The His tag impaired the secretion of GDNF, especially in the case of His-tagged proG-
DNF, but the Flag-tagged molecules seemed to be secreted in high amounts (I: Figure 1A). RET 
phosphorylation assays showed that all the tagged molecules (note that we did not test His-tagged 
proGDNF because of its poor secretion) are active (I: Figure 1D). Due to the secretion issue of 
His-tagged GDNF, we focused on further characterization of the Flag-tagged Gly-linked proteins 
(proFlagGGGDNF and FlagGGGDNF). CHO or HEK 293 cells were transfected with plasmids 
encoding ProFlagGGGDNF and FlagGGGDNF, and the media were collected one and two days 
later and analysed. The amount of the protein in the medium increases with time, and there is a 
difference between the cell lines, as proGDNF might be processed more in HEK 293 cells (I: 
Figure 1B). These results also show that mature GDNF can be secreted without the prosequence, 
at least when overexpressed. 
We also compared the effects of different media on the processing of GDNF. We trans-
fected CHO cells with plasmids encoding untagged proGDNF, ProFlagGGGDNF or FlagGGG-
DNF and grew them either in Dulbecco’s modified Eagle's medium (DMEM) + 10% fetal bovine 
serum (FBS) + 1% penicillin/streptomycin or OptiMEM® without FBS. We then collected and 
analysed media and lysates: in the presence of OptiMEM® the secretion of GDNF is less efficient 
(I: Figure 1C). 
As GDNF processing pattern is quite complex and gives rise to several bands visible on 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, we decided to 
sequence part of them to verify their identity. GDNF was partially purified, run on a reducing gel 
and then transferred on a PVDF membrane. We detected a difference in the band pattern. ProG-
DNF generated several bands, one of which was replaced by two bands when the ProFlagGGG-
DNF was analysed (I: Figure 2). We sequenced these two bands, and found that the heavier band 
corresponded to FlagGGGDNF (DYKDDDDKGGSPDKQMAVLP…), while the lighter band 
lacked the FlagGG and the first six amino acid residues of the sequence of mature GDNF 
(AVLP…). The single band generated by proGDNF was de facto a mixture of normal length 
mature GDNF (SPDKQMAVLP…) and shorter GDNF (AVLP…), showing that the novel cleav-
age site is not caused by the presence of the tag. We tried to study whether it was possible to 
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inhibit this cleavage by mutating one, two, or three amino acids located in this region 
(SPDKQM|AV → SPDKQA|AV, SPDKAA|AV, or SPDAAA|AV, | indicates the cleavage site). 
However, we did not detect any significant difference between the constructs (data not shown). 
 
6.2 GDNF is more stable when produced in mammalian cells  
GFLs are conserved among different species, but are not produced by bacteria in nature. 
However, it is possible to transform E. coli with plasmids encoding GDNF in order to produce 
large amounts of growth factor. This method has been used in order to produce GDNF for clini-
cal trials (listed in Table 2), but mammalian GDNF is known to be glycosylated (Lin et al., 1993, 
Ansorena et al., 2010) and the disulphide bonds present in the GDNF are fundamental for its 
function (Eigenbroth and Gerber, 1997). Neither of these modifications occurs in E. coli. In addi-
tion, the purification and subsequent in vitro renaturation of the molecule in general occur 
through a series of harsh steps (Lin et al., 1993, Hoane et al., 2000). The renaturation step is cru-
cial to obtain functional growth factors with disulphide bonds, but it probably forms proteins with 
slightly altered tertiary structure, and subsequently reduced biological activity (Hoane et al., 
2000). We therefore wanted to assess whether production of GDNF in a more natural environ-
ment would be beneficial for the stability and/or activity of the molecule. 
We transfected CHO cells with green fluorescent protein (GFP), tagged or untagged 
proGDNF, and collected the media two days later. E. coli GDNF was added to the medium from 
GFP-transfected cells, and all the media were subsequently incubated at 37 oC in the absence of 
cells. Results showed that E. coli GDNF is less stable than mammalian GDNF, regardless of the 
tag (I: Figure 4A). Stability of GDNF varies depending on the extracellular environment, and 
different cell types process the molecule differently (I: Figure 4C). Regarding the activity we 
performed RET phosphorylation assays on MG87-RET cells transfected with GFRα1 without 
detecting any difference in the strength or duration of the phosphorylation induced by either 
mammalian or E. coli GDNF (data not shown), but it has to be taken into account that this setting 
may not be sensitive enough.  
 
6.3 Glycosylation affects maturation of GDNF but not its receptor specificity 
GDNF is glycosylated (Lin et al., 1993), however, no studies have investigated where 
this modification specifically occurs and what its role is. First of all we decided to align the se-
quences of GDNF from several species to figure out whether this modification is conserved (Fig-
ure 8), and then to compare the sequences of human GFLs to verify whether the other members 
of the same family are also glycosylated (Figure 4). 
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Figure 8. Alignment of GDNF from differ-
ent species. Red: presequence, light blue: 
prosequence, green: finger structures, C: cyste-
ines involved in the knot, NXX: putative N-
glycosylation sites, the red vertical bar indi-
cates a predicted furin cleavage site. The se-
quences of GDNF (or fragments of it) from 
different species were aligned and analysed as 
described in Figure 4. 
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 The predictions point out that GDNF has two putative N-linked glycosylation sites (three 
in birds: G. gallus and N. nippon), which are conserved among birds, mammals, amphibians, and 
fish. 
We mutated the predicted glycosylation sites of human GDNF and expressed the protein 
in the presence of tunicamycin, which inhibits N-linked glycosylation. Results show that only the 
site located on the first finger (126NVT) is in use (I: Figure 3), at least in the cell line used (Chi-
nese hamster ovary cells, CHO). In our set up, glycosylation at this site is not important for re-
ceptor specificity (at least in the presence of high amounts of GDNF) or stability of the molecule 
(I: Figure 4B). However, we show that glycosylation at this site affects the processing and secre-
tion of GDNF: the amount of growth factor in the medium is lower, and it seems to be secreted 
mostly as proGDNF (I: Figure 3 and 4B). 
 
7. NRTN mutants: production, testing, and role of heparin binding 
7.1 Production and purification of the NRTN variants 
To create NRTN mutants, we decided to model the three-dimensional structure of NRTN 
(II: Figure 1A) based on homology with GDNF, one of the only two members of the family that 
have been crystallized (Eigenbroth and Gerber, 1997, Parkash et al., 2008). This was necessary in 
order to find the residues that could be involved in binding to heparin: the amino acids not only 
have to be part of a specific consensus sequence (Cardin and Weintraub, 1989), but they have to 
be aligned so that they point in the same direction. The heparin-binding residues are located in 
the helix, while studies on GFLs have shown that the regions important for binding to the recep-
tor are in the fingers (Eketjäll et al., 1999, Baloh et al., 2000, Parkash et al., 2008). Therefore we 
thought that mutations in this area would not have a major effect on receptor binding. The helix 
region is quite long and comprises several basic Arg residues, with more than one potential hepa-
rin-binding consensus sequence. For this reason, and because of the risk of generating non-
functional mutants, we decided to produce more than one variant (II: Figure 1B). The first three 
mutants (N1-N3) were planned based on the replacement of Arg with Ala in the helix region: N1 
and N2 have non-overlapping mutations, while in N3 we combined the mutations present in both 
N1 and N2, with the exception of the last Arg. This choice was made because this residue is con-
served in three out of four GFLs (Figure 4) and could therefore be important. The fourth variant 
(N4) was engineered by exchanging the helix of NRTN with that of PSPN and adding four extra 
residues to maintain the length of the helix. The reason for this choice is that PSPN does not bind 
heparin (Bespalov et al., 2011). For initial use we also produced N-terminally V5-tagged variants 
(NV1-4) in order to be able to detect the proteins with high sensitivity. In addition, to improve 
secretion, we cloned NRTN variants lacking the prosequence and harbouring the immunoglobu-
lin G signal sequence (Fjord-Larsen et al., 2005). 
We transfected CHO cells with plasmids encoding these mutants and verified the de-
creased affinity for heparin by affinity chromatography. All the variants presented decreased 
heparin affinity (II: Figure S1C). RET phosphorylation experiments with media from CHO cells 
transfected with plasmids encoding the NRTN variants showed that all the variants were active 
(II: Figure S1A-B), so we proceeded with their purification and functional testing. 
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To upscale NRTN production, the variants (without V5-tag and prosequence) were pro-
duced in CHO cells in suspension. We chose mammalian cells for NRTN expression to ensure a 
better quality of the molecule (Hoane et al., 2000).  
 
7.2 The NRTN variants have reduced affinity to heparin and two of them are more active 
than wild type NRTN in vitro 
As the NRTN variants had decreased affinity for heparin, and different pI values, the es-
tablished purification techniques for GFLs could not be used. We therefore developed a new 
method based on a first partial purification with a heparin column, and a second step based on 
affinity to GFRα2. After this procedure, we obtained relatively pure proteins (II: Figure 2); how-
ever, a small fraction of wild type NRTN and N2 lacked two amino acids at the N-terminus. 
Heparin affinity chromatography shows a decreased binding to heparin of the purified 
untagged NRTN variants (II: Figure 3, wild type NRTN eluted at 1.08 M NaCl, N1 at 0.97 M, 
N2 at N3 at 0.56 M, N4 at 0.48 M). Our decision to produce several mutants proved to be very 
good, as during heparin affinity chromatography assays N1 was really difficult to handle. In addi-
tion, when later the variants had to be concentrated for in vivo assays, both N1 and N3 had aggre-
gation and precipitation problems. We can speculate that these problems are due to the mutations 
they share, and that charges normally present in this area prevent NRTN molecules from aggre-
gation. However, it must be taken into account that also wild type NRTN has a strong tendency 
to aggregate and precipitate. 
The in vitro assays gave very interesting results. Immunocytochemical stainings (II: Fig-
ure 6A-B) show that when untransfected CHO cells are incubated with wild type NRTN, the 
molecule binds to the HSPGs present on the cell surface, while N4 fails to do so. However, when 
the cells are transfected with GFRα2, both variants can bind the receptor. Immunocytochemistry 
is not quantitative, so we decided to perform binding assays to verify whether there was a differ-
ence in the affinity for the receptor and the strength of the binding. Our binding assays performed 
on affinity columns show that binding of the NRTN variants to GFRα1 is weaker than to GFRα2 
(II: Figure S4). This is in line with what is known about wild type NRTN (Cik et al., 2000). On 
the affinity columns, in the absence of RET, the mutants seem to bind slightly more weakly to 
GFRα2 than wild type NRTN (II: Figure S4). The difference in the binding to GFRα2 is however 
abolished when RET is present on transfected cells (II: Figure 4A), in line with the fact that the 
receptor stabilizes the complex (Virtanen et al., 2005). We conclude that probably the mutation 
introduced altered slightly the orientation of the finger-like structures of NRTN, which are re-
sponsible for receptor binding. However, even if such a change had happened, its magnitude was 
not enough to have a significant effect on the binding of NRTN to its receptor. 
Once proved that the binding to GFRα2 and to GFRα2/RET was almost unaltered, we 
proceeded with several activity assays. There is apparently no difference in the doses at which 
wild type NRTN or the variants activate RET (II: Figure 4B) or promote survival of embryonic 
dopaminergic neurons (II: Figure 5A). This alone, would indicate that there is no superiority of 
any of the variants compared to the wild type protein. However, when the system where the mol-
ecules are tested gets more complex, N2 and N4 prove to be more efficient than wild type NRTN. 
One such example is the embryonic kidney explant culture (II: Figure 5B): NRTN is known to 
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work as autocrine factor in the kidney branching in vitro, but it does not induce extraureteric 
branching (Davies et al., 1999). This effect, however, is known to occur in the presence of GDNF 
(Sainio et al., 1997). Our variants N2 and N4, instead, promote such branching, probably because 
of their high stability. Western blots with samples taken from the media where the kidney ex-
plants were growing show that, while wild type NRTN is degraded, N2 and N4 are present even 
after 24 h (II: Figure 5B). The reason for the higher stability of N2 and N4 is not clear yet. How-
ever our studies suggest the involvement of an unknown protease which could cleave wild type 
NRTN but not the variants because of the mutations introduced (II: Figure S2B-D). This im-
proved stability has of course beneficial effects even in clinical use of NRTN, when the molecule 
could act longer on the degenerating and dying neurons. 
 
7.3 N4 improves neurorestoration and motor function in a rat 6-OHDA model of PD 
We injected wild type NRTN, N2, and N4 in the brains of naïve rats, measured the diffu-
sion volumes, and showed that N4 is the one that diffuses the most (II: Figure 6C-D). A similar 
diffusion was observed in the brain of two different monkey species (II: Figures S5 and S6), 
showing that the improved diffusion properties are maintained in other species. 
The benefits of the improved stability and diffusion are observed in in vivo experiments 
on rat models of PD. In this experiment we decided to compare the variants to GDNF produced 
in E. coli, which is more effective than NRTN in animal models of PD and has been used in all 
the GDNF-related clinical studies. We decided to administer a relatively high dose of 6-OHDA 
(28 µg 6-OHDA distributed to four striatal injection sites), followed by low amounts (5 µg) of 
neurotrophic factors. The neurotrophic factors were administered intrastriatally, two weeks after 
the lesion. This way we were able to compare the effects of the different treatments and see 
which one was the most effective. With a smaller lesion and saturating amounts of factors, we 
might not have been able to compare their activities. We tested the use of paws (cylinder test, II: 
Figure 7C) and measured amphetamine-induced rotations (rotation assay, II: Figure 7B). Nor-
mally animals use both their paws and do not rotate when administered amphetamine. A unilat-
eral lesion of dopaminergic neurons, however, causes the animals to use preferentially the ipsilat-
eral limb and to rotate toward the lesion side. If the administered neurotrophic factors rescue the 
dying cells, unilateral limb use deficiency gets smaller, and the number of rotations decreases. Of 
all the administered molecules (E. coli GDNF, N2, N4, and buffer), only N4 had a significant 
effect in both tests. When the brains of the animals were analysed, we observed that all the neu-
rotrophic factors used rescued the dopaminergic somata (II: Figure 7D), but only in animals 
treated with N4 also the axons were preserved (II: Figure 7E). GDNF and the two NRTN vari-
ants N2 and N4 have also been tested in monkey MPTP models of PD to measure their neuro-
restorative activity. The results are promising, and are currently being analysed by our collabora-
tors. They will form an article not included in this thesis. 
The NRTN variants, especially N4, have proved to be effective in a rat animal model of 
PD. However, in order to use them successfully in humans it is important to verify whether the 
component of the receptor complex are expressed in the brain regions of interest. We therefore 
verified using RT-PCR on a human brain sample that the mRNAs of Gfrα1, Gfrα2 and Ret are 
expressed in the striatum and in the SNpc (II: Figure 8B). 
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7.4 Binding to heparin causes increased accumulation of NRTN and earlier onset of RET 
signalling 
To verify that the decreased binding to heparin would not affect other important proper-
ties and to understand its potential importance, we compared accumulation, internalization and 
signalling of wild type NRTN and of NV4. 
Results show that the presence of HS, either on the cell surface or in soluble form in the 
medium, aids the accumulation of wild type NRTN on the cell surface. This is true not only in the 
absence of GFRα2 (II: Figure 6A-B), but also when GFRα2 (alone or together with RET) is pre-
sent (III: Figures 3 and 4). The higher amount of wild type NRTN can be detected both at 37oC 
and on ice, when the endocytosis is blocked. This indicates that the effect on the accumulation 
starts already at the cell surface level. 
We studied whether NRTN is internalized in the absence of RET. We performed assays 
using the LI-COR system, and CHO cells transfected with GFRα2 together or without RET, or 
untransfected cells (III: Figure 5). Our results show that wild type NRTN can bind the surface of 
CHO cells lacking either receptor and is subsequently internalized, while NV4 fails to do so. 
When GFRα2 is present, however, both variants bind it and are internalized, independently of the 
presence of RET. The total amount of internalized NRTN in the presence of RET seems however 
to be lower than when only GFRα2 is present. This could be due to increased degradation or to 
lower amounts of GFRα2 on the cell surface. Further experiments are needed to answer this ques-
tion. 
As the increased accumulation of wild type NRTN could have an effect on signalling, we 
decided to measure phosphorylation of RET, AKT and ERK in different cell lines (III: Figure 6). 
First, we transfected MG87-RET cells (which express RET) with GFRα2, and incubated them at 
37 oC with wild type NRTN or NV4 for different amounts of time. Results show no difference 
between the NRTN variants (III: Figure 6A). Then we repeated the experiment in CHO and pgsA 
745 cells transfected with both RET and GFRα2. These cell lines were chosen to study the effects 
of the presence of HS, as pgsA 745 is a mutant CHO cell line which does not produce HS. Also 
in this case there was no difference between the NRTN variants (III: Figure 6B). However, when 
we used Neuro 2A cells (which express both RET and GFRα2 at low endogenous levels), we 
detected a difference between wild type NRTN and NV4. Results show that wild type NRTN 
induces phosphorylation of RET already after a short incubation of 1 min, while NV4 fails to do 
so (III: Figure 6C). Therefore, our results indicate a correlation between a stronger affinity to 
heparin and a faster signal onset when the components of the recptor complex are expressed at 
endogenous levels. As GFRα2 has relatively high affinity to heparin (III: Figure 1) this faster 
onset could for instance be due to HSPGs acting as a link between NRTN and the co-receptor. 
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8. GDNF processing, stability, and glycosylation 
We show that the tagging, the cell line and the medium used can affect the processing of 
GDNF. This is critically important to take into account when producing proteins for clinical use, 
as the different processing of GDNF can result in different efficacy of the growth factor. Another 
thing to consider is the presence of a shorter form of mature GDNF, which lacks six residues at 
the N-terminus and is produced at least during overexpression of the growth factor. One could 
argue that this is not important because the binding to GFRα1 occurs through the fingers (Baloh 
et al., 2000), and the residues lacking in the shorter form of GDNF are not part of the heparin-
binding sequence (Alfano et al., 2007). However, tagging can be beneficial in experimental set-
tings order to recognize exogenous protein, and for purification. Therefore it is worth to consider 
this additional cleavage site when planning to N-terminally tag GDNF for experimental studies. 
The r-metHuGDNF used in clinical trials (Table 2) was produced in E. coli as mature 
protein. The possibility to obtain the same molecule from mammalian cells without the need to 
use harsh purification and renaturation steps is a very good alternative, especially when the goal 
is to produce high-quality GDNF for clinical use. We show that GDNF can be secreted from 
mammalian cells also when overexpressed without the prosequence. However, the prosequence 
of GDNF may be active on its own. Indeed, it has been shown that DNSP-11, a peptide com-
posed of 11 amino acids belonging to GDNF prosequence, has neuroprotective effects on dopa-
minergic neurons (Bradley et al., 2010). Due to low heparin affinity, DSNP-11 likely diffuses 
more than GDNF in the brain tissue (Kelps et al., 2011). It is not known if this peptide is natural-
ly cleaved from proGDNF, but if this was the case use of proGDNF could lead to unexpected 
side effects due to DSNP-11 activity and diffusion. On the other hand, the presence of the prose-
quence in expression constructs for mammalian cells seems to increase the amount of secreted 
pro- and mature GDNF. The prosequence could therefore be important, especially when deliver-
ing GDNF intracerebrally through viruses or encapsulated cells. It must also be taken into ac-
count that the two isoforms of GDNF (α-proGDNF and β-proGDNF) differ only in their prose-
quence but are differently secreted, as β-proGDNF, but not α-proGDNF, secretion is activity-
dependent (Lonka-Nevalaita et al., 2010). Therefore whether to include or not the prosequence 
and which one to choose might depend on the specific goals of the experiment or clinical trial. 
As mentioned, GDNF produced in E. coli is purified through several steps, including 
renaturation to reform disulphide bonds, which could affect its quality. In addition, since bacteria 
do not naturally N-glycosylate molecules or produce disulphide bridges, the molecule obtained is 
inevitably different from the mammalian one, even when cells are transformed with plasmids 
encoding the human sequence. However, clinical trials have so far been conducted with GDNF 
produced in E. coli. Because of possible differences due to the production system we wanted to 
verify whether the quality of GDNF produced in mammalian cells is functionally comparable or 
even superior to that produced in E. coli. Using RET phosphorylation assay we could not detect 
any differences in the activity of GDNF from E. coli or mammalian cells, but this could be due to 
the assay conditions. The experiments were in fact performed with excess GDNF amounts and 
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overexpression of the receptor complex and therefore the experimental conditions might not be 
sensitive enough to show possible differences (see also NRTN discussion).  
What we show, however, is that E. coli GDNF is less stable than mammalian GDNF. 
This could be due to the way the molecule is purified, to not correctly formed Cys bridges or to 
lack of glycosylation. We decided to study the last question in more detail. Human GDNF is pre-
dicted to be glycosylated close to the tip of the first finger and on the α-helix, just before a puta-
tive furin cleavage site. As the fingers are important for binding to GFRα1 (Eketjäll et al., 1999, 
Baloh et al., 2000, Parkash et al., 2008) glycosylation on the first predicted site could play a role 
in receptor specificity. Glycosylation on the second site, instead, could protect GDNF from deg-
radation, by making the predicted neighbouring furin cleavage site inaccessible to proteases (Fig-
ure 8). Our results indicate that only the first site is N-glycosylated (at least in the cell line used), 
and this is important for the processing and secretion of GDNF. Specifically, GDNF lacking gly-
cosylation is found in the medium mostly as proGDNF, while the mature unglycosylated mam-
malian protein is secreted only in very low amounts. However, both unglycosylated mammalian 
proGDNF and unglycosylated mammalian GDNF are more stable than E. coli GDNF. This sug-
gests that the lower stability of bacterially-produced GDNF is not due to absence of glycosylation 
but rather to suboptimal folding. 
Taken together, these results suggest a role of glycosylation in processing and secretion 
of GDNF, and show that mammalian GDNF is more stable than the one produced in E. coli. 
Compared to in vitro assays (1-100 ng/ml, see for instance Lin et al., 1993, Eigenbroth and Ger-
ber, 1997, Baloh et al., 2000), quite high concentrations of GDNF (3-100 µg in injection experi-
ments, 3-10 µg/day in chronic infusion) were used in in vivo experiments (see for instance Hoffer 
et al., 1994, Kirik et al., 2001, Piltonen et al., 2009) and in clinical trials (3-43 µg/day, see Table 
2). The need for higher doses could be due to a differential degradation of GDNF in the brain 
tissue (Hadaczek et al., 2010), to aggregation and subsequent precipitation, and/or to a non-
optimal quality of the protein. This last hypothesis is supported by the fact that whenever mam-
malian GDNF has been used in animal models, much lower doses were sufficient to promote 
survival of dopaminergic neurons. As an example, in AAV-GDNF treated animals (Kirik et al., 
2000) 0.22-2.28 ng GDNF/mg tissue was found in the injected tissue, and when animals were 
transplanted encapsulated cells the initial secretion of these capsules was 26.4-67.9 ng/day (Ki-
shima et al., 2004, Sajadi et al., 2006). In some animal experiments (Kirik et al., 2001) continu-
ous injections of E. coli-produced GDNF have been used. Therefore the difference in the doses 
cannot be explained by a different experimental paradigm (single protein injection versus contin-
uous cell secretion).  
 
9. Affinity of NRTN to heparin: two sides of the same coin  
Taking all our results into account, we conclude that the improved diffusion and stability 
of the N4 NRTN variant are important for its higher efficacy compared to wild type NRTN and 
GDNF. N4 is more active than wild type NRTN in promoting extraureteric budding in kidney 
explants, and more effective than GDNF in restoring dopaminergic fibres and motor function in a 
rat model of PD. Another factor that could account for the improved activity of N4 compared to 
E. coli GDNF could also be the production of the NRTN variant in mammalian cells. The im-
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proved diffusion and stability probably affect the activity of N4 so that this variant reaches a 
higher number of neurons and induces survival or regeneration of their axons and not only of 
their somata. The effect on axons is reflected in the results of the behavioural assays. 
HS and CS are essential components of the ECM, but their exact composition is most 
likely different in different species (see for instance Lu et al., 2010). However, we show that N4 
diffuses more than wild type NRTN in rats, and more than GDNF in two different monkey spe-
cies (cynomologus and marmoset monkeys). If the improved diffusion feature is conserved in 
humans, treatment with N4 could be more beneficial than treatment with E. coli-produced GDNF 
or AAV2-NRTN.  
On the other hand, we report that the presence of HSPGs on the cell surface or in the me-
dium aids the accumulation of wild type NRTN, but does not affect that of N4. The increased 
accumulation of wild type NRTN results in a more effective signalling in Neuro 2A cells. This 
cell line expresses GFRα2 and RET endogenously, and therefore at lower levels than transfected 
CHO, pgsA 745 or MG87-RET cells: this is perhaps the reason why the assay is more sensitive 
and the difference between the variants can be measured. One could wonder whether this differ-
ence in the amount of factor on the cell surface should not affect the activity of the proteins in-
jected in the brain so that N4 would be less active than wild type NRTN. We have not used wild 
type NRTN in our in vivo setup, but we can speculate that, as GDNF is also binding HSPGs, the 
presence of HSPGs could affect the accumulation of GDNF (and therefore its activity) similarly 
to what happens with wild type NRTN. However, in the in vitro activity assay N4-containing 
medium was replaced with DMEM after 1 min, while when injected into the brain the molecule 
is continuously present and has therefore more time to act. This way, the only apparent deficit of 
N4 is overcome and the molecule proves to be superior to GDNF for in vivo use. 
Similar mutagenetic approaches might be useful to improve the diffusion of the other 
GFLs (of course with the exception of PSPN). As a matter of fact, GDNF variants with lower 
affinity to heparin have already been patented (Leung et al., 2012). However, it is extremely im-
portant to plan the mutation carefully: we modelled the three-dimensional structure of NRTN to 
study which amino acid residues were correctly aligned in space, but in other GFLs the heparin-
binding region can be localized somewhere else. In GDNF, for instance, the N-terminus is im-
portant for binding to heparin (Alfano et al., 2007), but the helix contains only a few basic resi-
dues. In that case, replacing the α-helix with that of PSPN would have failed to generate mutants 
with increased diffusion. In the same way, to generate ARTN variants, the exact sequence and 
structure have to be considered, and only after a careful analysis the mutation(s) can be planned. 
Ideally, they should not be located on the fingers, as mutation of these structures could affect 
receptor binding, and mutations with positive effects on the stability could also be desirable. In 
our case, the residues important for heparin binding are located in the heel region (Figure 4, resi-
dues 146-158), so their mutation does not significantly affect the interaction with the receptors. In 
addition, introduction of the helix of PSPN improves the stability of NRTN, as N4 is more stable 
than the wild type protein. 
Another way to improve the diffusion of neurotrophic factor could be the use of different 
types of viral vectors. AAV5 viruses have lower affinity to heparin than AAV2 viruses (Opie et 
al., 2003), and could therefore diffuse better once delivered to the brain. However, this type of 
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therapy would require better titration, as diffusion of AAV5-GDNF outside the SNpc has been 
shown to cause robust weight loss in animal models (Manfredsson et al., 2009). In addition, the 
use of AAV vectors does not allow precise regulation of the amount of neurotrophic factor. 
Therefore at the actual state, delivery of purified mammalian protein might still be preferable. 
We also show that both wild type NRTN and N4 can be internalized when GFRα2 but 
not RET is present. There is therefore a RET-independent internalization pathway, which could 
be related to the interactions with N-CAM (Paratcha et al., 2003), but this still has to be analysed 
in more details. A similar conclusion can be made for GFRα2-independent NRTN internalization, 
since we show that wild type NRTN can be internalized even in the absence of this receptor if 
there are HS on the cell surface. This internalization could be caused by interactions with HSPGs 
(Bespalov et al., 2011), but, again, more studies have to be performed. The significance of this 
result in in vivo context is still to be determined.  
The use of NRTN in PD clinical trials is of course useful only if RET and GFRα1 and/or 
GFRα2 are expressed in the relevant areas of the brain (striatum and/or SNpc). Studies on GFRα1 
knock-out E12 mouse embryos (Cacalano et al., 1998) show that their dopaminergic neurons do 
not benefit from the presence of GDNF of NRTN, unless also exogenous GFRα1 (Cacalano et al., 
1998) or GFRα2 (Wang et al., 2000) are added. These results lead to the important conclusion 
that both GDNF and NRTN can promote dopaminergic neuron survival, if either GFRα1 or 
GFRα2 is present. Considering this, the failure to rescue dopaminergic neurons in GFRα1 knock-
outs suggests that GFRα2 is not present on these neurons in new born mice, or at least its levels 
are too low to mediate an effective signalling. This is in accordance with in situ hybridization 
data which show that in developing and adult mice (Widenfalk et al., 1997, Wang et al., 2000) 
and in adult rats (Marco et al., 2002) Gfrα1 mRNA is expressed by the nigral dopaminergic neu-
rons, but Gfrα2 mRNA is mostly expressed by neighbouring cells. Only a subpopulation of do-
paminergic neurons located in the deep midbrain expresses low levels of Gfrα2 mRNA. These 
observations generate the conclusion that, at least in mice models of PD, the rescuing activity of 
GDNF and NRTN is mediated by GFRα1. In our study we show that, in adult humans, mRNAs 
encoding GFRα1, GFRα2 and RET are present both in the striatum and in the nigra (II: Figure 
8B). However, we performed PCR on tissue samples which contained several cell types, and 
therefore our results do not specifically demonstrate the expression of GFRα1-2 or RET in neu-
rons (or dopaminergic neurons). There can also be developmental differences and humans, mice 
and rats might have a different expression pattern of the receptor. Walker and colleagues (1998) 
show that Ret and Gfrα1 mRNAs are expressed in the SNpc of PD patients. The levels of Ret 
mRNA vary between samples. The authors mention that they cannot make conclusions about the 
biological relevance of this finding because it is not known what levels of RET are required to 
confer responsiveness to GDNF. Moreover, they do not comment on the stage of PD, and their 
analysis of the expression of Gfrα1 mRNA is based on one patient only. Bäckman et al (2006) 
measured the expression of Gdnf, Gfrα1 and Ret mRNAs in the putamen of PD cases, and 
showed that the expression levels of the components of the receptor complex are unchanged in 
PD patients compared to age-matched controls. Taken all this into account, and considering that 
NRTN can signal through GFRα1, there are good reasons to think that our NRTN variants with 
improved diffusion might have a positive effect on PD patients. 
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CONCLUSIONS 
 
This thesis was conducted to obtain better understanding on the post-translational modi-
fications of GDNF and on the heparin binding feature of NRTN. These studies have interesting 
implication for clinical use of GDNF and NRTN.  
 
The main conclusions from this work are: 
I. Glycosylation on the first finger of GDNF does not affect stability of the growth 
factor or its receptor specificity. 
II. GDNF produced in mammalian cells is more stable than GDNF produced in E. 
coli. 
III. The affinity of NRTN to heparin is correlated to a more effective onset of intra-
cellular signalling. 
IV. The helix of NRTN can be modified without affecting significantly the interac-
tion of the growth factor with the receptor. The mutation increases diffusion and 
stability of the growth factor. 
V. The increased diffusion and stability lead to higher efficacy of NRTN in a rat 6-
OHDA model of Parkinson’s disease.  
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Figure 7. A. Synthesis of CS. In dermatan sulphate, the GlcA of the repeating disaccharide unit is replaced 
by IdoA. B. Synthesis of HS. Yellow: Xyl, green: Gal, light blue: GlcA, red: GalNAc, lilac: GlcNAc.  
 
The sugar structure is then sulphated: CS have long tracts consisting of modified disac-
charides. Some types of sulphation are present both in CS and HS, but others are specific for each 
type: for instance only CSs present GlcA-3-O-sulphation. Other modifications consist in 4-O- 
and 6-O-sulphation of GalNAc, and 2-O-sulphation of the uronic acid (Zhang, 2010). 
 CSs are typically involved in structural and regulatory activities. For instance, as compo-
nents of the ECM, they are important for the integrity of tissues like cartilage (Dijkgraaf et al., 
1995). In the CNS, CS have a regulatory role: they are for instance the fundamental components 
of the perineuronal nets (PNNs) in the brain and in the visual cortex. PNNs are specialized struc-
tures of the ECM which have a role in the closure of critical periods. During the critical period, 
sensory experience shapes the organization of the neuronal network, which is plastic at this stage. 
For example, in the visual cortex of young rats the PNN is not completely formed: this allows 
plasticity and correct organization of the neuronal connections. However, the cortex of adult rats 
with a well-developed PNN is less plastic. This is partially due to CSPGs which are present in 
adult rats, but not in younger animals. It has been shown that digestion of CSPGs with chon-
droitinase ABC restores the neuronal plasticity in adults (Pizzorusso et al., 2002). However, some 
CS have apparently different functions: a class of CS (CS-E) is instead promoting axonal growth 
in a cell-specific fashion (Mikami and Kitagawa, 2013). 
GDNF binds CS with high affinity (10-fold higher than affinity to HS) and with almost 
no dissociation. It has therefore been proposed that CS could keep holding neurotrophic factors 
while presenting it to the receptor, or that growth factors could be enzymatically released from 
such molecules (Nandini et al., 2004). However, CS does not seem to be important for GDNF 
signalling, as this is not decreased in cells lacking CSPGs, and exogenously added CS had only a 
slight effect on GDNF activity (Barnett et al., 2002). 
 
4.2 Heparan sulphate proteoglycans (HSPGs) 
Synthesis of HSPGs starts in the same way as that of CSPGs. The difference arises when 
the fifth sugar is added to the linker sequence: in the case of HSs this is GlcNAc, and the repeat-
           A                                             B 
